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ABSTRACT 
Metabolic heart disease (MHD) caused by obesity or diabetes is characterized by 
cardiac hypertrophy, diastolic dysfunction, and fibrosis – a maladaptive remodeling of 
the extracellular matrix. Though the influence of cardiac fibrosis on the left ventricular 
diastolic dysfunction has been reported, little is known about the cardiac-specific secreted 
autocrine, paracrine, or endocrine factors termed “cardiokines” in MHD. Transforming 
growth factor β1 (TGF-β1) is a well-known inducer of cardiac fibrosis. However, the role 
TGF-β2 in mediating cardiac fibrosis has yet to be described. In addition, follistatin-like 
3 (FSTL3), an extracellular inhibitor of activin A and myostatin, is found to be elevated 
in end-stage heart failure patients and obese individuals. FSTL3 has been suggested as a 
cardiokine, yet its role in MHD has not been established.  
To identify cardiokines induced by MHD, two relevant mouse models were 
employed in this study: the high-fat high sucrose (HFHS) diet feeding model and the 
cardiomyocyte-specific Fatp1 overexpressing transgenic mouse model. Interstitial 
fibrosis was observed in both models, accompanied by fibrotic gene expression and anti-
fibrotic miR-29 suppression. It was found that Tgf-β1 and Tgf-β2 mRNA were 
upregulated by 85% and 76%, respectively, in the non-myocytes of 1-month HFHS-fed 
  xii 
mice, while Fstl3 was increased by 30% in the myocytes. In contrast, in the FATP1 
transgenic animals, Tgf-β2 and Fstl3 were elevated by 3.8-fold and 1.9-fold in the 
myocytes while Tgf-β1 remained unchanged compared to control animals. The in vitro 
results tested in NIH3T3 and primary fibroblast cultures indicate that both TGF-β1 and 
TGF-β2 exerted profibrotic effects via activation of SMAD proteins and collagen 
synthesis, but FSTL3 did not. Plasma samples collected from patients with metabolic 
syndrome showed increased FSTL3 levels with strong correlations with cardiac 
hypertrophy and impaired diastolic function. 
Overall, this study has demonstrated that TGF-β1 and TGF-β2 are the key 
profibrotic cardiokines induced in MHD. The study has also revealed the role of FSTL3 
as a biomarker for LV hypertrophy induced in MHD. The results presented here should 
facilitate the development of better diagnosis and treatment for this disease in the future. 
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Chapter 1: Introduction 
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1.1 Metabolic Heart Disease 
 The metabolic syndrome leading to cardiovascular diseases (CVD), such as heart 
failure (HF), is a major cause of morbidity and mortality in industrialized countries. The 
obesity epidemic alone is a serious and costly condition affecting more than one-third or 
78.6 million adults in the United States as reported by the Center for Disease Control and 
Prevention (1). The burden of obesity on the U.S. economy was $147 billion annually 
with the obese patients spending $1,429 more each year on medical costs than healthy 
normal weight individuals (2). On the other hand, HF is diagnosed in 5.1 million 
American adults (3)and is estimated to grow to more than 8 million by 2030(4). The 
mortality and morbidity of HF is more heinous than most cancers given the fact that 
mortality rate within 5 years of initial diagnosis is ~50% (5). The total spending in direct 
medical costs, services, and medication for HF was estimated to be $30.7 billion in 2012 
and is expected to increase to $69.7 billion by 2030 (4). The impact of the metabolic 
syndrome on human mortality and socioeconomic burden demands novel approaches to 
better diagnose, treat, and manage these health conditions. 
The metabolic imbalance underlying obesity has fueled the prevalence of 
metabolic syndrome – a constellation of interrelated risk factors of metabolic origins that 
together promote the increased risk of cardiovascular disease (CVD) and type II diabetes 
(6-8). Ever since the metabolic syndrome was first introduced by Gerald Reaven in 1988 
(9), a number of definitions have been proposed by organizations including the National 
Cholesterol Education Program (NCEP), the International diabetes Federation, and the 
World Health Organization. The Third Report of the NCEP’s Adult Treatment Panel 
 
 
 3 
published in 2001 has emerged as the commonly used definition, as it provides a 
relatively simple approach for diagnosing the metabolic syndrome by employing easily 
measurable risk factors. Specifically, the NCEP defines the metabolic syndrome as least 3 
of the following 5 cardiovascular risk factors: 1) central obesity (waist circumference: 
men >102 cm; women >88 cm); 2) elevated triglycerides (≥150 mg/dl); 3) diminished 
high-density lipoprotein (HDL) cholesterol (men >40 mg/dl; women >50 mg/dl); 4) 
systemic hypertension (≥130/ ≥85 mm Hg); and 5) elevated fasting glucose (≥110 mg/dl) 
(10, 11). The magnitude that each risk factor plays in elevating the overall risk of CVD is 
variable, but insulin resistance and central obesity have been reported as the key 
determinant of the metabolic syndrome (12). Currently 15% of the total population is 
diagnosed with metabolic syndrome (13), increasing the risk of developing CVD by 2-
fold and mortality by 1.5-fold within 5 to 10 years after diagnosis, compared to an 
individual without the syndrome (12). 
 The type of HF induced by metabolic syndrome, which is referred to as metabolic 
heart disease (MHD), develops left ventricular hypertrophy and impaired diastolic 
function with preserved ejection fraction (14). In the case of HF with systolic 
dysfunction, numerous interventions are currently available, such as angiotensin-
converting-enzyme inhibitors and beta-adrenergic blockers. However, for HF with 
diastolic dysfunction and preserved systolic function, very limited treatments are 
available beyond diuretic or vasodilators (15) to alleviate the symptoms. This unmet need 
calls for better therapeutics for HF with diastolic dysfunction beyond the status quo, 
which requires first a better understanding of the mechanism of the disease. Myocardial 
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fibrosis of the LV often present in HF is found to correlated with the severity of diastolic 
dysfunction (16). The treatment of fibrosis is particularly challenging, as the timing is 
critical and early diagnosis would depend on reliable biomarkers.  
In the setting of metabolic syndrome, elevated circulating free fatty acids (FFA) is 
found in the cardiomyocytes, which can overwhelm intracellular beta-oxidation rates, 
leading to ectopic lipid accumulation in the heart as well as other metabolically active 
tissue such the liver, and pancreas (13). The excessive lipid uptake can lead to 
detrimental effects on the normal functions of cells in these organs, but the exact 
molecular mechanisms of lipid-induced cellular dysfunction has yet to be fully 
investigated. The role of ectopic lipid content in the pathogenesis of MHD has been 
implicated by increased cardiac contractility dysfunction in obese rodents, in contrast, 
when lipid content is reduced the cardiac function is improved (17, 18). Furthermore, the 
increased triglyceride level often found in metabolic syndrome patients is an independent 
predictor of diastolic function (19).  
 
1.2 Cardiac Fibrosis 
The extracellular matrix (ECM) is structurally a large assemblage of a variety of 
complex macromolecules surrounding the cell. Primarily, the ECM contains the 
proteoglycans, collagens, elastin fibers, fibronectin, and other integral basement 
membrane components. Under normal physiological conditions, the ECM in the heart 
tissue supports the transmitting force generated by cardiomyocytes into organized systole 
(contraction) and passive stiffness in diastole (relaxation) to prevent over-stretching (20), 
 
 
 5 
cellular slippage (21), and tissue deformation. Beyond its role of structural support, the 
ECM also serves as a site for storage for proteases and latent growth factors that regulate 
fibrosis, growth, differentiation, and angiogenesis (22) once their activation is triggered 
by injury or stress.  
As stated earlier, an important hallmark of HF with myocardial hypertrophy 
induced by the metabolic syndrome is the cardiac fibrosis, a process of excessive 
accumulation of collagens and other ECM components into the interstitial space and 
perivascular regions of the myocardium (23). Generally, the collagens are the most 
abundant proteins in the ECM, and in the heart specifically, the fibrillar collagens, type I 
and type III, are the dominant collagens. The two types of cardiac fibrillar collagens form 
a tropocollagen composed of three chains in a triple helix. Once secreted into the ECM, 
multiple tropocollagens are covalently crosslinked by lysyl oxidase to form collagen 
fibrils and multiple fibrils subsequently form the collagen fiber. While type I collagen 
mainly provides tensile strength and structural support, type III provides elasticity of the 
network. In fibrosis, the once organized collagen slats and networks formed in the 
interstitial space are disrupted and replaced with the disorganized array of fibrils (22, 24) 
(Figure 1).  
Since the mature fibrillar collagens have a half-life of 80-120 days (25) the 
dynamic balance between synthesis and degradation becomes an important determinant 
for ECM turnover. This balance is largely maintained by a family of matrix 
metalloproteinases (MMPs) (26) and family of endogenous tissue inhibitors of  
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Figure 1 Fibrosis of the heart. 
(A) Under normal physiology, the collagen fibers form organized tensile bundles that are 
nicely organized to provide support for cardiac cells, particularly cardiomyocytes. (B) In 
the event of cardiac stress, fibrosis is activated causing the accumulation of excess ECM 
deposits and disorganization of the collagen network. Spinale FG, Circ. Res., 1999, and 
Am. J. Physiol., 1991.  
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metalloproteinases (TIMPs). The MMPs, especially MMP-3, 9, and 13 can breakdown 
collagens and other ECM component polypeptides. To counter the proteolytic activities 
of MMPs, the TIMPs can directly inhibit the MMP enzymatic activation, which in turn 
promotes collagen stability and ECM accumulation (27). Thus, as a result of tipping the 
balance towards more synthesis and less degradation, fibrosis is promoted. Taken 
together, strategies to ameliorate or slow down synthesis early enough in the fibrotic 
phase are needed for the treatment of cardiac fibrosis induced in HF. 
Though there are two different types of fibrosis, reparative and reactive (28), it is 
still unclear as to whether these are in fact two distinct mechanisms of actions. The 
reparative fibrosis refers to the scar formation developed when excessive cell death 
occurs, as in ischemia or senescence. The reactive fibrosis refers to the increased ECM 
deposition around the interstitial space surrounding cardiomyocytes and vessels in 
response to direct stimulation of fibroblasts without cell injury, as is the case in MHD. 
Interstitial fibrosis specifically refers to the fibrotic remodeling around the 
cardiomyocytes. The development of interstitial fibrosis has been linked to impaired LV 
function, both in systolic function (29) and diastolic function (16, 30). Currently, the 
exact mechanism responsible for triggering the transition from normal collagen synthesis 
to excessive fibrosis is not known but there is evidence for local growth factors and 
plasma hormones in mediating the fibrotic response.  
In addition to the ECM components that contribute to the cardiac fibrosis, the 
transforming growth factor beta-1 (TGF-β1), angiotensin II (Ang II), endothelin-1 (ET-1) 
and ROS have also been implicated in the disease. The specific mechanism of TGF-β1  
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will be discussed in greater detail in a later section, but briefly, TGF-β1 is a potent 
inducer of ECM metabolism via the activation of SMAD proteins that bind to its co-
activators to upregulate the transcription of ECM genes, primary collagen and CTGF. 
Ang II as a potent vasoconstrictor and inducer of increased blood pressure has been found 
to be elevated in the myocardium of pressure overloaded and infarcted heart with fibrosis 
(31, 32). It has been reported that Ang II induces cardiac fibrosis by upregulating TGF-β1 
through the angiotensin II type I receptor (AT1) (33). ET-1, also a powerful 
vasoconstrictor synthesized in endothelial cells, induces ECM production and is a 
downstream target of both TGF-β1 and Ang II. TGF-β1activates ET-1 production 
through JNK signaling (34) while Ang II activates ET-1 through ERK and ROS (35). 
Collectively, the evidence suggests a network of proteins act in concert to contribute to 
the activation and persistence of myocardial fibrosis.  
Beyond extracellular protein and hormone regulation the fibrotic process, it has 
become increasingly clear in recent years that microRNAs (miRNAs) are a major player 
in the molecular regulation of fibrosis as well. The miRNAs are endogenous non-coding 
RNA molecules approximately 22-nucleotide long that regulate protein synthesis at the 
post-transcriptional level by commonly targeting the 3’UTR region of the mRNAs 
(Figure 2) (36). Several miRNAs have been identified to impact cardiovascular 
physiology (37-39), four miRNAs in particular have been implicated to play a pivitol role 
in the regulation of cardiac fibrosis – miR-29, miR-21, miR30, and miR-133. These four 
miRNAs have distinct molecular targets and cellular expression, as depicted in Figure 3. 
First the miR-29 family has shown to directly target a large network of ECM proteins  
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Figure 2 MicroRNA synthesis and function. 
Primary transcriptions of miRNAs called pri-miRNAs are transcribed from either intron 
regions or polycistronic regions of mRNA genes. The pri-mRNA is subsequently 
processed by Drosha RNase into a hairpin-shaped precursor miRNA (pre-miRNA) 70-
100 nucleotides long.  Once pre-miRNA is exported into the cytoplasm, it is cleaved by 
Dicer into a miRNA:miRNA duplex. The duplex is assembled into the RISC complex, 
where the mature miRNA ~22 nucleotides-long negatively regulates gene expression by 
translational repression by targeting the 3’UTR region target mRNA for mRNA 
degradation. van Rooij E. J. Clin. Invest, 2007. 
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including collagens, fibrillin, fibronectin, and elastin (40). The downregulation of miR-29 
together with increased ECM gene expression in the bordering zone of the infarct region 
signifies the relief from the normal anti-fibrotic action of miR-29 (40). MiR-21 has been 
shown to be upregulated post-MI as an enhancer of ERK signaling through the targeting 
of a negative regulator of the ERK pathway, sprout homolog 1 (Spry1). MiR-21 also 
activates PI3K-Akt pathway by targeting its negative regulator phosphatase and tension 
homolog (PTEN) to promote MMP2 synthesis. (41). Both miR-21 and miR-29 are found 
exclusively in the cardiac fibroblasts (40, 41). As mentioned earlier CTGF is upregulated 
by TGF-β1 signaling and has been established to create a favorable environment for 
fibrogenic stimuli to act downstream (42). Accordingly, miR-133 and miR-30 
expressions are downregulated with increased cardiac fibrosis in hypertrophic and HF 
patients (43). Both miR-133 and miR-30 repress CTGF expression with the difference 
that miR-133 is expressed in cardiomyocytes and miR-30 in fibroblasts (43). Direct 
downregulation of miR-29 expression by TGF-β1 has been reported via SMAD3 binding 
(44) while other reports have reported that miR-29 expression downregulation is induced 
by  TGF-β2 but not TGF-β1 (45). With the identification of miRNAs that regulate a 
network of related ECM genes, there is immense therapeutic potential to exploit this 
innate regulatory process for the treatment of cardiac fibrosis.  
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Figure 3 MicroRNA in cardiac fibrosis. 
In response to stress signals, microRNAs are altered in the heart to mediate fibrosis. In 
the cardiac fibroblasts, miR-21 is upregulated while miR-29 and miR-30 are 
downregulated. In the cardiomyocytes, miR-30 and miR-133 are downregulated. miR-21 
represses Spry1, a negative regulator of ERK-MAP kinase signaling. miR-29 represses 
expression of collagens and other ECM components. miR-30 and miR-133 repress the 
expression of CTGF, a positive co-regulator of fibrosis. van Rooij E and Olson EN. Cir. 
Res., 2009. 
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1.3 Cardiokines 
In obesity, many organs that are affected by the imbalance of lipid and glucose 
metabolism respond to the pathological stresses by secreting autocrine, paracrine, and 
endocrine factors. The most notable example is the adipose tissue, which secretes 
adipokines, including adiponectin, leptin, tumor necrosis factor-α, interleukin-1β. These 
cytokines can modulate inflammatory and metabolic processes locally and distally, such 
as to the heart (46). The cytokine proteins produced by the heart, which may function 
much the same way as adipokines in signaling both locally and peripherally, are referred 
to as cardiokines. With the demand for new biomarkers in CVD diagnosis and 
therapeutics, the total number of identified cardiokines has been steadily increasing to a 
conservative estimate of 30-60 cardiokines based on the presence of the N-terminal 
sequence that are predicted to target the protein for classic secretory pathway (47, 48).  
Cardiokines are secreted from all types of cells found the heart including 
myocytes, fibroblasts, and vascular cells. The number of cardiokines have been identified 
for their abilities to modulate cardiomyocyte hypertrophy, cardiomyocyte survival and 
apoptosis, fibroblast activation, and inflammation(49-51). Atrial natriuretic peptide 
(ANP) and brain natriuretic peptide (BNP), the two circulating cardiokines originating 
from cardiomyocytes, are found elevated in HF. Their endocrine effect is thought to 
counteract HF by promoting vasodilation and inhibiting Ang II and aldosterone, whereas 
their autocrine and paracrine effects are believed to inhibit cardiomyocyte hypertrophy 
and fibroblast activation (52). BNP has also been used as the gold stand biomarker to 
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detect LV hypertrophy (53-55). TGF-β1 is a cardiokine, which is elevated in pathological 
states to promote recruitment of inflammatory cells, cardiomyocyte hypertrophy, or 
fibroblast activation (56, 57). Cardiac secretion of Ang II is also induced in HF to 
activate cardiomyocyte hypertrophy and fibrosis, as discussed earlier. New cardiokines 
are continuously being discovered, for instance, the growth differentiation factor-15, 
myostatin, activin A and follistatin-like 3 have been demonstrated to protect 
cardiomyocytes from apoptosis post-myocardial infarction, increase skeletal muscle 
wasting, suppress myocyte hypertrophy and promote fibroblast activation, respectively 
(58-61).  
Many of the cardiokines reported have been induced under the stress of 
myocardial infarction (MI) or pressure overload (PO). However, cardiokines that may be 
induced specifically under MHD stress remain to be precisely identified. It is too early to 
preclude the possibility that the cardiokines induced may overlap between MI, PO, and 
MHD, particularly since fibrosis and hypertrophy are the common phenotypes among 
these diseases. However, considering the differences in etiology and the underlying 
mechanisms of MI, PO, and MHD, the identification the key cardiokines induced 
specifically by MHD is still important as it may shed light on the development of novel 
or better diagnostic tools and treatment therapies for this disease. 
 
1.4 Transforming growth factor beta family 
 The transforming growth factor beta family (TGF-β) of secreted cytokines is 
critical to a diverse range of cellular functions, ranging from inflammation, extracellular 
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matrix deposition, cell proliferation, differentiation, and growth (62, 63). In mammals, 
three distinct genes encode the three structurally similar TGF-β isoforms, including TGF-
β1, - β2, and -β3. The TGF-β glycoproteins are synthesized and secreted into the ECM as 
immature precursor proteins, non-covalently bound to the latency-associated peptide 
(LAP) domain. The LAP domain prevents TGF-β from binding to its receptors until its 
removal through the proteolytic activity of thrombospondin-1 (TSP-1) (64). Once 
released from the LAP, the active TGF-β molecule is able to bind with high affinity to its 
constitutively active serine/threonine type II TGF-β receptors, evoking a conformational 
change that activates the recruitment the appropriate type I TGF-β receptor, then the type 
II receptors phosphorylate the type I receptors in the glycine/serine-rich domain to 
activate intracellular signaling (62).  
The downstream signaling pathways of TGF-β receptor type I activation include 
the Sma and Mad (SMAD)-dependent and SMAD-independent pathways as depicted in 
Figure 4. The classic SMAD pathway begins with the activation of receptor-activated 
SMADs (R-SMADs) 2 and 3, which then recruits SMAD4 (co-SMAD) to translocate into 
the nucleus. Once inside the nucleus, the SMAD2/3/4 complexes together with its 
binding partners to activate or repress the transcription of target genes. Several studies 
have reported SMAD-independent pathways, via the activation of extracellular signal-
regulated kinase (ERK), c-Jun-N-terminal kinase (JNK), p38 mitogen-activated kinase 
(MAPK), Abelson non-receptor tyrosine kinase (c-Abl) and TGF-β activated kinase 1 
(TAK-1) (65). 
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Figure 4 TGF-β signaling pathways. 
TGF-β signaling is activated through binding to high-affinity type II receptors which will 
trans-phosphorylate and recruit type I receptors to initiate intracellular signaling. The 
SMAD pathway is activated via first the recruitment of receptor-activated (R-) SMADS 
2/3 or SMAD1/5. A complex is formed with SMAD4, a co-SMAD, to translocate to the 
nucleus and binding with co-activator or co-repressors to regulate targeted gene 
expression. Non-SMAD activated signaling includes extracellular signal-regulated kinase 
(ERK), c-Jun-N-terminal kinase (JNK), p38 mitogen-activated kinase (MAPK), Abelson 
non-receptor tyrosine kinase (c-Abl) and TGF-β activated kinase 1 (TAK-1). 
Dobaczewski et. al. JMCC., 2011 
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Although the three TGF-β isoforms have similar structures and signaling 
activities, recent evidence suggests that they have different expression patterns and non-
overlapping functions. TGF-β1 is by far the most ubiquitously expressed isoform in many 
organs and cell types. In the heart, TGF-β1 is markedly elevated in animal models of HF 
and is associated with cardiac hypertrophy and fibrosis. However, specific role of the 
other TGF-β isoforms in modulating myocardial remodeling remains unknown. Only a 
few reports have shown elevated TGF-β2 and TGF-β3 in the stressed heart. Early 
upregulation of TGF-β2 along with TGF-β1 have been reported in the infarct area in a 
rodent model of MI, with a delayed elevation of TGF-β3 (66). Additionally, in the 
myocardial biopsies taken from patients with dilated cardiomyopathy, expressions of 
TGF-β2 with TGF-β1 were upregulated (67). Also informative of the importance of each 
individual TGF-β isoform are the knockout mice. Of the TGF-β1 null mice, a half of the 
animals die in utero due to defective yolk sac vasculogenesis and hematopoiesis while 
those that survive birth succumb to death caused by multi-organ inflammation, primarily 
in the heart and lungs (68, 69). TGF-β3 knockout mice exhibit defective epithelial-to-
mesenchymal transition leading to cleft palate and abnormal lung development (70). 
TGF-β2 null mice exhibit perinatal mortality and sever developmental organ defects, 
including congenital heart defects (71). TGF-β2 is indispensible for the embryonic 
development of cardiac tissue as shown by cardiac valvular defects in TGF-β2 null mice 
(72). The cardiac expression of Tgf-β2 has been observed in the myocardial, endocardial, 
neural crest, and vascular smooth muscle cell lineages (72-74), which implies the 
importance of the autocrine and paracrine activity of TGF-β2. However, due to the 
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perinatal mortality of TGF-β2 knockout it has been difficult to study the role of TGF-β2 
in adult cardiac pathogenesis. 
 Under the larger umbrella of TGF-β superfamily are the ligands myostatin and 
activin A. Both myostatin  and activin A activate downstream signaling using the 
receptor SMAD2 and SMAD3 (75, 76). Further downstream, myostatin has been shown 
to have an inhibitory action on skeletal muscle growth by inhibiting phosphorylation of 
AKT (protein kinase B) (77). Due to its inhibitory effects on skeletal muscle growth, 
myostatin plays a critical role in the development of muscle wasting disease, cachexia, 
which increases the risk of heart failure (78). Additionally, cardiac expression of 
myostatin have been observed in failing human hearts (79). More recently, Activin A has 
been suggested as an even more potent inducer of cachexia via the activation of the 
Activin IIB receptor (80). In the heart, activin A expression is upregulated following 
ischemic injury and pressure overload (60, 81). The protective effects of Activin A have 
been demonstrated in vitro to rescue myocytes from apoptosis under the stress of 
hypoxia/reoxygenation (60), as well as the prevention of cardiac injury following 
systemic delivery of Activin A in vivo post-ischemia/reperfusion (82). In summary, the 
diverse functions of TGF-β superfamily ligands are broad and complex, with both similar 
and non-overlapping functions. 
1.5 Follistatin family 
 The follistatins family is a group of extracellular regulators that can each 
selectively bind to members of the TGF-β superfamily, including activin A, myostatin, 
and BMPs. The follistatin family consists of follistatin (FST) and follistatin-like 3 
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(FSTL3), which are structurally and functionally related glycoproteins (82, 83), and a 
distantly related follistatin-like 1 (FSTL1), which has little or no overlap to the rest of the 
family. FST and FSTL3 have been identified for their angatonistic activities against 
activin A and myostatin (84, 85), while FSTL1 has been identified to antagonize the 
activity of BMP1 (86). Though FST and FSTL3 have many similarities their differential 
expression suggests non-overlapping actions. FST has the highest expression in ovaries, 
testis, and kidney, while FSTL3 has the highest expression in placenta followed by testis, 
pancreas, and heart (85).  
The importance of FST and FSTL3 has been underscored by the phenotypes 
developed with the individual gene ablation. Full body Fst knockout led to severe 
developmental defects in the mice resulting in perinatal fatality (87). Since FST was 
originally discovered to be produced in pituitary gonadotrope and folliculostellate cells 
based on its inhibitory actions on follicular stimulating hormone (FSH) (88), ovary-
specific knockout of Fst led to the premature cessation of ovarian activity (89). In 
contrast, FSTL3 null mice survived to adulthood but developed a host of metabolic 
phenotypes, including decreased visceral fat mass, improved glucose tolerance and 
enhanced insulin sensitivity, that could help glucose-intolerant obese patients (90). More 
recently, increased plasma FSTL3 levels have been observed in obese individuals with 
body mass index greater than 30, and is associated to increased fat mass (91). Together, 
this suggests that decreased FSTL3 in patients may improve outcomes in patients.  
Specifically in the heart, increased FSTL3 was observed in the myocardium of 
end-stage heart failure patients, with a positive correlation to disease severity (92). In the 
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same study, cardiomyocytes and endothelial cells were identified to be the source of 
elevated FSTL3 expression. Myocardial infarction (60) and pressure overload (81) in 
mice resulted in increased FSTL3 and activin A expression. The cardioprotective role of 
activin A and the opposing force of Fstl3 are highlighted in the decreased infarct size 
when cardiomyocyte specific Fstl3 knockout mice were subjected to ischemic injury(60). 
FSTL3 has also been shown to play a role in myocardial hypertrophy as cardiac-specific 
ablation of Fstl3 attenuated cardiac hypertrophy in response to pressure overload (81). In 
cultured neonatal myocytes, PE-stimulated hypertrophic response was significantly 
prevented with Fstl3 siRNA pretreatment (81). The contribution of myocyte-derived 
FSTL3 to cardiac fibroblast activation was shown in cultured neonatal fibroblasts treated 
with recombinant FSTL3, where full activation required its purported binding partner 
connective tissue growth factor (CTGF) (61). Taken together, it is clear that FSTL3 plays 
an important role in mediating both hypertrophy and fibrosis under the ischemic and 
pressure overloaded stress. Therefore, it is critical to determine whether FSTL3 is also 
affected under metabolic stress that contributes to the development of cardiac 
hypertrophy and fibrosis.  
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1.6 Hypothesis 
  We hypothesize that there is an increase in one or more cardiokines that play a 
key role in the pathophysiology of diet-induced MHD. 
 
1.7 Specific Aims   
1. To identify cardiokines induced by dietary excess and their effects on the heart 
 
2. To determine the role of cardiokines induced by lipid accumulation in the heart 
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Chapter 2: Materials and Methods 
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2.1 Reagents 
Unless otherwise noted, all chemicals were obtained from Sigma Aldrich and used as 
received without further purifications other than sterile filtering in some cases.  
  
2.2 HFHS diet mouse model of MHD 
 The HFHS-fed mouse accurately mimics the clinical features of the human 
metabolic syndrome and enables us to study the aspects of the disease pertinent to this 
project (impaired diastolic function and increased cardiac interstitial fibrosis) in a 
pathophysiologically relevant mouse model (93). Significant gain in body weight and 
myocardial wall thickness has been observed with 3 months and 2 months on HFHS diet, 
respectively. Concurrently, relaxation (diastolic) abnormalities have also been observed 
early in the diet feeding time course, developing significant differences by 4 months and 
plateauing thereafter. Secondary systemic effects of the diet begin to develop at or after 4 
months on diet, including glucose intolerance, diabetes, renal and liver failure. The 
fibrotic signaling data used cardiac tissue collected from mice fed on diet for 2 weeks to 4 
months. Whereas the characterization of the cardiac functions tracked mice fed on diet 
for 1 month to 8 months. The control diet (D09071703) and HFHS (D09071702) were 
purchased from Research Diets. A detailed breakdown of the ingredients in both diets is 
shown in Table 1.  
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 Control Diet HFHS Diet 
 Breakdown: gm%  kcal%  gm%  kcal%  
Protein  15 15 20.5 15 
Carbohydrate  76.3 75 38.2 28 
Fat  4.5 10 35.5 58 
Total kcal/gm  4.05 100 5.54 100 
Ingredient: gm  kcal  gm  kcal  
Casein  182 728 182 728 
DL-Methionine  3 12 3 12 
Maltodextrin 10  170 680 170 680 
Corn starch  760 3040 0 0 
Sucrose  0 0 164 656 
Lard  55 495 320 2880 
Salt Mix, S10026B  50 0 50 0 
Vitamin Mix, V10001  10 40 10 40 
Choline Bitartrate  2 0 2 0 
Total  1232 4995 901 4996 
 
Table 1 Control and HFHS diet breakdown 
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2.3 FATP1 transgenic mouse model of MHD 
 The cardiac FATP1 transgenic mouse was developed by Chiu et al. (94) using 
alpha myosin heavy chain (α-MHC) promoter to drive cardiomyocyte-specific 
overexpression of hemagglutinin (HA) tagged FATP1 in FVB/N mice. The reported 4-
fold increase in FATP1 protein expression leads to a 4-fold increase in myocardial FFA 
uptake and 2-fold cardiomyocyte FFA accumulation (94). More specifically, net 
diacylglycerol increased in FATP1 hearts, with no change in ceramide, sphingomyelin, or 
acylcarnitine species (95). Genotyping for FATP1 transgenic mice used the primer pair 
listed below at the annealing temperature of 60°C for 34 cycles. 
 FWD 5’-CCATACGACGTCCCAGACTACGC-3’ 
REV 5’-TGTGCCCAGGCAGAAGGCCAGG-3’ 
2.4 FSTL3 knockout mouse model 
The cardiomyocyte-specific Fstl3 knockout (KO) mice were generated by 
crossing homozygous Fstl3flox/flox (96) with transgenic mice overexpressing Cre-
recombinase controlled by α-myosin heavy chain promoter (α-MHC-Cre) obtained from 
The Jackson Laboratory; both in the C57BL/6 background. The Fstl3flox/flox has two loxP 
sites flanking exons 3-5 of the Fstl3 allele. The first generation Cre+/-;Fstl3flox/+ offsprings 
were subsequently crossed with Cre-/-;Fstl3flox/flox obtain homozygous Fstl3 KO. For 
genotyping PCR, four pairs of primers were used to detect Fstl3 and Cre genes. Tail 
snips were taken and digested with REDExtract-N-Amp Tissue PCR Kit (Sigma) to 
obtain genomic DNA. The genotyping PCR reaction for the two pairs of primers had an 
annealing temperature of 58°C and ran for 40 cycles. For the detection of loxP site at 
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intron 2 with the following primer pair: 
SJL954  5’-TCTGAGAAGAGGAGGGATTTCAAG-3’  
SJL955  5’-ATTTACACCTAGCCACATACTCTG-3’ 
The presence of the loxP site yields a 390-bp amplification product, while the wild-type 
Fstl3 yields a 330-bp fragment. Concurrently, the α-MHC-Cre transgene is detected with 
the following primers: 
9543 Fwd 5’-ATGACAGACAGATCCCTCCTATCTCC-3’  
9544 Rev 5’-CTCATCACTCGTTGCATCATCGAC-3’ 
oIMR8744 iFwd 5’-CAAATGTTGCTTGTCTGGTG-3’ 
oIMR8745 iRev 5’-GTCAGTCGAGTGCACAGTTT-3’ 
As shown in Figure 5, the PCR products were separated by agarose gel electrophoresis 
(1.8% agarose and 0.01% GelRed nucleic acid stain, Biotium).  
A detailed breeding strategy is outlined in Figure 6. The resulting KO (Cre+/-
;Fstl3flox/flox) with Fstl3 exons 3-5 deleted was compared the control mice (Cre+/-
;Fstl3+/+). At baseline, no differences in heart weight/body weight and lung weight/body 
weight ratios were detected between control and KO mice (81). Similarly, no difference 
was reported between WT C57BL/6 mice and that carrying Cre transgene at baseline (81). Mice (8-9 weeks old) were put on HFHS or control diet (CD) for 1 month. 
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Figure 5 Genotyping FSTL3 Knockout Mice. 
Two loxP sites flank exons 3-5 of Fstl3 gene and polymerase chain reaction is 
used to amplify the gene product to detect the presence of the first loxP insertion. 
Forward primer (SJL954) and backward primer (SLJ955) amplify a DNA product of 370 
base pairs in the presence of loxP and 330 base pairs without loxP (wild-type Fstl3). 
Genotyping using tail tissue is shown in the agarose gel: 1) a homozygous Fstl3 floxed 
animal with no Cre, 2) heterzygous Fstl3 floxed animals with one copy of Cre, and 3) 
homozygous Fstl3 floxed animal with one copy of Cre. 
3 4 5  loxP  loxP 2 1 
Floxed'allele:%%370%bp WT#allele:########330#bp 
Floxed'Fstl3'allele: 
3.8$kb$deletion 
Floxed'Fstl3'allele WT#Fstl3#allele 
Cre:%%300bp Internal( Control 
1"""""""""""2""""""""""3" 
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Figure 6 Fstl3 knockout breeding strategy 
Mouse breeding strategy to generate cardiomyocyte-specific knockout of Fstl3.  
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2.5 Picrosirius red staining 
Mice were euthanized and the ventricular structures were isolated in cold PBS on 
ice. A slice of the left ventricular free wall was taken and fixed in formalin overnight. 
Paraffin-embedded tissue sections (4µm) were made and allowed to adhere on positively 
charged glass slides overnight at 37°C. The tissue sections were then immersed in xylene 
for 10 minutes at room temperature and allowed to slowly rehydrate into water using 
descending ethanol concentrations of 100%, 95%, and 80% for 10 minutes each. 
Rehydrated sections were then fixed in pre-warmed Bouin’s fixative at 55°C for 1 hour. 
Next the slides were stained with Wiegert’s iron hematoxylin (Sigma) for 6-7 minutes at 
room temperature. Following thorough washes, sections were stained with Picrosirus Red 
A (PolySciences) for 2 minutes, rinsed, and then stained with Picrosirus Red B 
(PolySciences) for 1 hour at room temperature. Finally, the tissue slides were dehydrated 
with ascending ethanol content of 70%, 95%, and 100%, and then cleared in two dips of 
xylene. The stained tissue was mounted with Eukitt quick-hardening mounting medium 
(Fluka Analytical) over night. Then images were taken with the Olympus BX 40 
microscope on magnifications 4x, 10x, and 20x. The picrosirius red positive stains were 
quantified by Image J (NIH, Bethesda, MD).  
 
2.6 Mouse cardiac myocyte and non-myocyte isolation 
Mouse cardiomyocyte fraction was isolated by adapting from methods previously 
described for adult rat ventricular myocyte (97). Here we used eight-week-old FATP1 
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and wild-type (WT) littermates to obtain mouse cardiomyocyte fractions. In brief, mice 
were anesthetized with isoflurane and the hearts were removed and cannulated via the 
ascending aorta. The hearts were perfused with sterile isolation buffer (1 mM Glucose, 
0.5 mM Taurine, 1 mM 2,3-Butanedione monoxime, 135 mM NaCl, 5.4 mM KCl, 1 mM 
MgCl2, and 10 mM HEPES, pH 7.4). For enzyme digestion, hearts were perfused with 
0.5% collagenase B, 0.5% collagenase D, and 0.04% protease in isolation buffer for 5-7 
minutes. Digested hearts were disconnected from the apparatus and collected in 35 mm 
culturing dishes with 1% BSA in isolation buffer. Following enzymatic inhibition with 
BSA, the digested hearts were gently teased apart with fine tweezers, fully dissolved via 
pipetting, and filtered through mesh into 15 mL centrifuge tubes. After the cell 
suspension was allowed to settle for 15 min at room temperature, heavy myocytes formed 
a pellet while non-myocytes, including fibroblasts and endothelial cells, remained 
suspended in the supernatant  
 
2.7 ARVM isolation and treatment 
Primary adult rat ventricular myocytes (ARVMs) were isolated from male 
Sprague-Dawley rats (175-225 g) as described previously (97). In brief, the heart was 
rapidly isolated and attached through the aorta to a retrograde perfusion system. First, the 
heart was perfused with 37°C!Ca2+!free!Krebs!Henseleit!Buffer!containing!118 mM 
NaCl, 4.75 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, at pH 7.4. 
Next, the heart was digested with recirculating collagenase (Worthington) and 
hyaluronidase (Sigma-Aldrich) for 18-20 min. Following the initial digestion, the heart 
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was manually cut into small pieces and incubated in a collagenase/hyaluronidase enzyme 
cocktail supplemented with 1 mM CaCl2, trypsin, and DNAse for 20-25 minutes in a 
37°C!water!bath!with!light!agitation.!The!digested!heart!pieces!were!filtered!through!a!100Bμm!nylon!mesh!gauze,!centrifuged!at!500!rpm!for!3!min,!and!resuspended!in!wash!buffer!containing!equal!parts!DMEM,!1!g/L!LBglucose,!and!Ca2+!free!Krebs!Henseleit!Buffer.!Due!to!gravity,!heavy!ARVMs!fall!to!the!bottom!of!the!falcon!tube!while!nonBmyocytes!–!mainly!fibroblasts,!smooth!muscle!cells,!endothelial!cells!–!remain!in!the!suspended!in!the!supernatant,!which!is!further!centrifuged!at!1000!rpm!for!3!min!for!the!isolation!of!adult!rat!ventricular!fibroblasts!(ARVF).!The!pellet!containing!myocytes!was!washed!twice!with!wash!buffer!and!allowed!to!settle!10!min!per!wash.!The!pellet!was!then!gently!layered!on!a!bovine!serum!albumin!(BSA)!gradient!and!allowed!to!settle!for!15!min.!The!resulting!pellet!containing!primarily!of!viable!myocytes!was!resuspended!and!plated!on!laminin!coated!dishes!in!“ACCT”!media!composed!of!DMEM!with!1!g/L!LBglucose!(Life!Technologies)!supplemented!with!0.2%!BSA,!2!mM!Carnitine,!5!mM!Creatine,!5!mM!Taurine,!2.5!M!Hepes,!and!0.1%!penicillinBstreptomycin!for!1!hr!for!myocytes!to!attach!to!the!laminin.!Finally,!the!unattached!and!dead!cells!were!removed!with!a!fresh!ACCT!media!change!and!cells!were!allowed!to!incubate!overnight!prior!to!experimentation.!!
For PKC activation, ARVMs were treated with phorbol 12-myristate 13-acetate (PMA). 
Stock PMA was reconstituted in DMSO at 100 μM. ARVMs were treated with ACCT 
media supplemented with either 100 nM PMA or DMSO for 24 hours at 37°C. 
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2.8 ARVF cell culture and treatment The!supernatant!was!removed!and!further!centrifuged!at!1000!rpm!for!3!minutes!and!washed!twice!with!culturing!media!containing!DMEM!with!4.5!g/L!LBglucose!(Life!Technologies)!and!10%!FBS!(Atlanta!Biologicals,)!and!1%!penicillinBstreptomycin.!Only!first!to!third!passages!of!ARVFs!were!used!for!in!vitro!experiments.!For!experimental!conditions,!cells!were!split!1:3!into!p60!plastic!culturing!dishes,!serum!starved!overnight!and!incubated!with!experimental!media!of!low!glucose!(1!g/L)!DMEM!(Gibco,!Life!Technologies)!supplemented!with!human!recombinant!proteins!Fstl3, Tgf-β1, or Tgf-β2!(10!ng/mL,!R&D!Systems)!or!vehicle!control!(4!mM!HCl!containing!1!mg/mL!fattyBacid!free!BSA).!RNA!was!collected!24!hours!after!treatment.! 
2.9 NIH3T3 fibroblast culture and recombinant human protein treatment 
 NIH3T3 embryonic fibroblasts were cultured in DMEM supplemented with 4.5 
g/L glucose and 10% FBS (Atlanta Biologicals) and 1% penicillin-streptomycin. Cells 
were grown in 75cm2 flasks to sub-confluence and split 1:3 every three days. For in vitro 
experiments, 3T3 cells plated onto p60 plastic culturing dishes were allowed to attach 
prior to overnight serum starvation.  
Experimental media containing recombinant human Fstl3, Tgf-β1, or Tgf-β2!(20!ng/mL,!R&D!Systems)!or!vehicle!control!(4!mM!HCl!containing!1!mg/mL!fattyBacid!free!BSA!)!in!DMEM!replaced!the!starvation!media!next!day.!To!detect!
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phosphorylation!signals,!3T3!cells!were!treated!with!experimental!media!for!30!minutes.!To!detect!collagen!protein!synthesis,!3T3!cells!were!treated!for!24!hours.!!!!
2.10 RNA Isolation 
 Mice left ventricular tissue were snap frozen in liquid nitrogen and was physically 
pulverized in pre-chilled pestle and mortar with liquid nitrogen. Next, the tissue lysis, 
organic extraction, and total RNA elution was performed using the mirVana Kit (Life 
Technologies). No additional homogenization step was needed prior after the tissue lysis 
step included in the mirVana kit. Otherwise, cultured NIH3T3 and ARVF cells were 
washed twice with PBS then lysed with Trizol (Life Technologies). Subsequent organic 
extraction and RNA isolation used either the RNeasy MiniKit (Qiagen) or manually 
extracted with phenol:chloroform, ethanol, and 200 mM NaCl. The eluted RNA from 
columns and reconstituted RNA pellet from manual method were subjected to DNase 
digestion (Ambion, Life Technologies) for 30 min prior to reverse transcription. 
2.11 Real-time quantitative PCR 
2.11.1 mRNA gene expression 
Total RNA was treated with DNase (Life Technologies, Calsbad, CA) prior to 
cDNA synthesis with High Capacity RNA-to-cDNA Kit (Life Technologies, Calsbad, 
CA) using between 450ng-1ug of starting RNA. One in fifty dilution of cDNA was then 
used for the subsequent qPCR reaction with TaqMan Gene Expression Master Mix (Life 
Technologies) ran on the StepOnePlus system (Life Technologies). Detailed list of  
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Species Gene Name Symbol Taqman Primer 
Mouse Angiotensinogen Agt Mm00599662_m1 
Mouse Brain natriuretic peptide Nppb Mm00435304_m1 
Mouse Collagen I, alpha 1 Col1a1 Mm00801666_g1 
Mouse Collagen I, alpha 3 Col1a2 Mm01165187_m1 
Mouse Collagen III, alpha 1 Col3a1 Mm01254476_m1 
Mouse Collagen IV, alpha 5 Col4a5 Mm00801606_m1 
Mouse Elastin Eln Mm00514670_m1 
Mouse Endothelin-1 Edn Mm00438656_m1 
Mouse Fibrilin-1 Fbn1 Mm00514908_m1 
Mouse Fibronectin-1 Fn1 Mm01256744_m1 
Mouse Follistatin Fst Mm00514982_m1 
Mouse Follistatin-like 1 Fstl1 Mm00433371_m1 
Mouse Follistatin-like 3 Fstl3 Mm00473194_m1 
Mouse Glyceraldehyde-3-
phosphate dehydrogenase 
Gapdh Mm99999915_g1 
 
Mouse Mmp 2 Mmp2 Mm00439498_m1 
Mouse Mmp 3 Mmp3 Mm00440295_m1 
Mouse Mmp9 Mmp9 Mm00442991_m1 
Mouse Mmp13 Mmp13 Mm00439491_m1 
Mouse Mmp14 Mmp14 Mm00485054_m1 
Mouse c-Myc Myc Mm00487804_m1 
Mouse Transforming growth 
factor 1 
Tgfb1 Mm01178820_m1 
Mouse Transforming growth 
factor 2 
Tgfb2 Mm00436955_m1 
Mouse Timp1 Timp1 Mm00441818_m1 
Mouse Timp2 Timp2 Mm00441825_m1 
Mouse Timp3 Timp3 Mm00441826_m1 
Mouse Timp4 Timp4 Mm01184417_m1 
Rat Collagen I, alpha 3 Col1a2 Rn01526721_m1 
Rat Collagen III, alpha 1 Col3a1 Rn01437681_m1 
Rat Glyceraldehyde-3-
phosphate dehydrogenase 
Gapdh Rn01775763_g1 
Mouse, Rat, 
Human 
Mature hsa-mi29a-3p 
 
miR-
29a 
002112 
 
Mouse, Rat, 
Human 
Mature hsa-mir29b-3p 
 
miR-
29b 
000413 
 
Mouse, Rat, 
Human 
Mature hsa-mir29c-3p 
 
miR-
29c 
000587 
 
Mouse snoRNA202 sno202 001232 
 
Table 2 Information for Taqman primers used in this study. 
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Taqman primers for mRNA gene expressions are listed in Table 2. Only 1 ul of primer 
was used for each well of reaction. The results of the qPCR runs were analyzed with the 
accompanying StepOnePlus software. ΔCT for each target gene expression was calculated 
by normalizing to Gapdh expression. Next, the average ΔCT value of control samples was 
used to normalize all samples to in order to generate the corresponding ΔΔCT for control 
samples and test samples. Subsequently the formula 2−ΔΔCT was applied to generate 
relative target gene expression with control sample set to “1”. 
2.11.2 microRNA gene expression 
 Taqman MicroRNA Reverse Transcription Kit (Life Technologies, Calsbad, CA) 
for microRNA. Used StepOnePlus (Life Technologies) to run the qPCR reaction and 
accompanying software for analysis. ΔCT for each target gene expression was calculated 
by normalizing to snoRNA202 expression and ΔΔCT subtracts the average of expression 
of control sample expression. Subsequently the formula 2−ΔΔCT was applied to generate 
relative target gene expression with control sample set to “1”.  
 2.11.2 PCR Array 
 RT2 ProfilerTM PCR Array was performed per manufacture’s instruction (Qiagen, 
Hilden, Germany) with the inventoried Mouse Fibrosis Array (PAMM-120Z). Total of 
1.5 µg of total RNA samples of FATP1 (n=2) and WT (n=2) were provided to the Boston 
University Analytical Core for processing. The complete list of target genes analyzed 
with PCR array listed in detail in Table 5.  
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2.12 Western blotting 
2.12.1 Whole heart tissue lysates 
Whole heart protein lysates were made from freeze-clamped hearts using lysis buffer 
which contains 20 mM Hepes pH 7.4, 50 mM β-glycerol phosphate, 2 mM EGTA, 1mM 
DTT, 10 mM NaF, 1mM NaVO4, 1% Triton-X100, 10% glycerol, and protease inhibitor 
cOmplete mini tablet-EDTA free (Roche) and were subjected to SDS-PAGE with protein 
content quantified using the Pierce BCA assay (Thermo Fischer). After transfer, PVDF 
membranes were blocked with LiCor blocking buffer (LiCor) for 90 minutes and blotted 
overnight with specific primary antibodies. Membranes were washed with TBS 
containing 0.1% Tween-20 three times for 5 minutes prior to the addition of IR-dye 
labeled secondary antibodies for 1 hour. A detailed list of primary and secondary 
antibodies used is shown in Table 3. The probed membranes were visualized using the 
Li-Cor Odyssey IR imager and the densitometry was analyzed with the Odyssey 2.1 
software. All proteins blotted were normalized to the GAPDH or total non-
phosphorylated protein expression. 
2.12.2 NIH3T3, ARVF, ARVM, protein lysates 
NIH 3T3 and ARVFs protein lysates were made using lysis buffer 25 mM Tris, 
50 mM Sodium chloride, 0.5% Sodium deoxycholate, 2% NP-40, 0.2% SDS, pH 7.4 with 
protease inhibitor complete mini-tablet-EDTA free and phosphatase inhibitor PhosSTOP 
(Roche). Lysates were quantified using BCA assay (Pierce, Life Technologies). Lysate  
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Antibody Supplier Species Dilution 
Col III Abcam Rabbit 1:1000 
FLRG (FSTL3) R&D Systems Goat 1 ug/ml 
GAPDH Abcam Mouse 1:15,000 
Goat IgG Li-Cor Biosciences Donkey 1:10,000 
Mouse IgG Li-Cor Biosciences Donkey 1:10,000 
P-Smad1/5/8 Cell Signaling 
Technology 
Rabbit 1:500 
 
P-Smad2/3 Cell Signaling 
Technology 
Rabbit 1:500 
 
Rabbit IgG Li-Cor Biosciences Donkey 1:10,000 
T-Smad1/5 Cell Signaling 
Technology 
Rabbit 1:500 
T-Smad5 Cell Signaling 
Technology 
Rabbit 1:500 
T-Smad2/3 Cell Signaling 
Technology 
Rabbit 1:500 
Tgf-B1 (2Ar2) Abcam Mouse 1:500 
Tgf-B2 R&D Systems Rabbit 1 ug/ml 
 
 
Table 3 Information for antibodies used in this study. 
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samples were diluted with either 2x Laemli sample loading buffer (Bio-Rad) or 6x 
Laemli sample loading buffer. Samples were boiled at 95°C for 5 min before they were 
subjected to SDS-PAGE. ARVMs were lysed with 1x lysis buffer (Cell Signaling) 
containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 
1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 
ug/mL leupeptin supplemented with 1 mM PMSF. The cells lysed on ice for 30 minutes 
and afterwards the lysates were cleared by centrifugation (13,000 rpm, 10 min, 4 °C). The 
pellet was discarded and supernatants were collected for protein quantification using 
BCA assay (Pierce, Life Technologies). Proteins were then diluted with additional lysis 
buffer and 2x Laemli sample loading buffer (Bio-Rad). Samples were boiled for 95°C for 
5 min before subjected to SDS-PAGE. For all western blots, between 30 and 50 µg of 
protein was loaded for each lane. 
2.13 Adenovirus construction, amplification, and purification 
Adenoviral vector expressing full-length murine Fstl3 was constructed by Ken 
Walsh’s lab (60). The recombinant adenovirus was generated following the AdEasy 
System protocols (QBiogene) with modifications. In brief, the full length Fstl3 cDNA 
obtained from American Type Culture Collection was subcloned into an adenovirus 
shuttle vector. Enzymatic digestion with PmeI was used to linearize the vector. Following 
linearization, the shuttle vector was co-transfected into competent TOP10 cells 
(Invitrogen) containing the large AdEasy-1 cosmid. Next, the recombined Fstl3 
adenovirus was extracted from TOP10 cells and transfected into HEK 293A cells.  
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For the virus amplification low passage HEK 293A cells, maintained in 1 g/L 
Glucose DMEM (Life Technologies) supplemented with 5% FBS and 1% penicillin-
streptomycin were used. Sequential series of adenoviral transductions were needed to 
increase cell culture volume in a step-wise fashion to achieve viral particle concentration 
of up to 1 x 1012. In between each scale up step, viral particles were released by 3 cycles 
of freeze/thaw from −80°C to 37°C. After collection of the viral particles at the last stage 
of amplification, cells were pelleted and only 5 mL of total volume was left freeze/thaw. 
The final cell/DMEM suspension was transferred to a 15 mL conical tube and the cell 
debris was removed via centrifugation at 2000 rpm for 10 min. The supernatant was 
carefully removed and purified with cesium chloride (CsCl) gradient. 
For the final viral purification, two CsCl gradients were used. First, a 
discontinuous gradient consisting of a high density (1.4 g/cm3) CsCl phase on the bottom 
and low density (1.2 g/cm3) CsCl phase layered above, and viral particles sitting on top. 
This step removes most of the cellular debris and a majority of the defective viral 
particles. Centrifuged at 100,000 g for 90 min and sharp white band will appear with a 
clear pink and clear phase separation. The white band was carefully removed with an 18-
gauge needle. Next, a continuous gradient was prepared by gradually mixing the high 
density CsCl with the low density CsCl and overlaying the viral particles collected by the 
18 gauge needed in the previous step. After the continuous gradient was centrifuged 
overnight at 100,000 g a sharp white band was visible and was collected. Finally, viral 
particles was removed any trace CsCl as it is toxic to cells with a buffer exchange (10 
mM Tris pH 8.0, 2 mM MgCl2, 4% sucrose) performed three times using a sterile 
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dialysis cassette (Thermo Scientific, Slide-A-Lyzer). The purified the viral particles was 
collected from the cassette, aliquoted and stored in -80°C.  
2.14 Statement on animal use 
 All animals were treated in accordance with approved Institutional Animal Care 
and Use Committee protocols at Boston University School of Medicine.  
 
2.15 Metabolic syndrome patient selection process 
 Detailed subject selection has been previously described (98). In brief, patients 
with metabolic syndrome (MS) who attended outpatient visits at general cardiology, 
hypertension, obesity, and nutrition clinics at Boston Medical Center were recruited. MS 
was defined as meeting 3 or more of the following criteria: (a) increased waist 
circumference (≥102 cm in men or ≥88 cm in women), (b) increased fasting triglyceride 
(≥150 mg/dl), (c) high blood pressure (≥130/85 mm Hg) or antihypertensive therapy, (d) 
decreased high-density lipoprotein cholesterol (<40 mg/dl in men or <50 mg/dl in 
women), and (e) impaired fasting glucose (≥100 mg/dl) (14). Controls without MS were 
recruited at Boston Medical Center and were defined as meeting none of the 5 criteria for 
MS. Participants with existing cardiovascular disease including heart failure, left 
ventricular ejection fraction (LVEF) <50%, coronary artery disease, or valvular heart 
disease were excluded from the study. All participants underwent a comprehensive 
medical history, physical examination and comprehensive echocardiographic assessment, 
including assessment of diastolic function using Tissue Doppler Em (mitral annular 
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myocardial diastolic velocity). LV mass was adjusted by dividing LV mass obtained from 
echocardiography by height (LVH_ht). 
 
2.16 Assessment of plasma Fstl3 protein concentration 
Blood was drawn from all subjects from antecubital fossa, centrifugated to obtain 
EDTA-plasma samples, which was then stored at -80ºC until analysis. All samples were 
analyzed simultaneously using a commercially available Follistatin-like 3 ELISA kit 
(Human FLRG Quantikine ELISA Kit, R&D Systems), a sandwich ELISA kit. The 
minimum detectable dose of this ELISA kit is between 2.01-8.55 pg/mL. Plasma NT-pro-
BNP levels were measured with a competitive ELISA kit, BNP Fragment EIA (Alpco). 
The detectable range of the BNP ELISA kit has a detection range between 200-6400 
pmol/L.  
 
2.17 Statistical analysis 
2.16.1 mRNA, microRNA, protein analysis 
Statistical analyses were performed with either the two-tailed Student’s t-test or 
analysis of variance, ANOVA, with Bonferoni post-test where appropriate using Prism 
software (GraphPad). All data shown were obtained from independent in vitro 
experiments and littermate-matched or controlled in vivo experiments. Data are expressed 
graphically as mean ± standard error. Statistical significance was set to p-value less than 
0.05. 
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2.16.2 Human plasma analysis 
All data are expressed as mean ± standard deviation unless otherwise stated. 
Normal distribution was tested for all continuous variables. Subjects were separated into 
4 groups by tertiles of Em and LVH_ht: highest Em/lowest LVH_ht tertile, highest 
Em/highest LVH_ht tertile, lowest Em/lowest LVH_ht tertile and lowest Em/highest 
LVH_ht tertile. Comparisons between multiple groups were made using ANOVA with 
Bonferroni post-hoc tests. Correlations between continuous variables were made with 
univariate linear regression. These analyses were performed with SPSS version 20 
software (IBM). For all analyses, a P value of < 0.05 was considered to be statistically 
significant. 
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Chapter 3. Cardiokines are induced by a dietary excess model of MHD 
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3.1 Rationale 
The myocardium is composed primarily of cardiac myocytes, fibroblasts, 
endothelial cells, and smooth muscle cells. Interestingly, cardiomyocytes take up about 
30-50% of total cell population but account for about 75% of the myocardial volume (99, 
100). On the other hand, while cardiac fibroblasts make up about 25% total cell 
population (100) they are primarily responsible for the collagen-rich fibrotic remodeling 
of the extra cellular matrix in response to extracellular signals proteins. Within the heart, 
many of the extracellular signals are cardiokines produced by cardiomyocytes, 
fibroblasts, endothelial cells, or vascular smooth muscle cells that act in an autocrine, 
paracrine, or in some cases, endocrine manner. Many of the cardiokine that have been 
identified have been discovered in the setting of myocardial infarction or pressure 
overload (101, 102). Considering that MHD is of a metabolic origin, it would be 
beneficial to determine whether cardiokines relevant to MHD prior to the progression of 
heart failure, whether they are the same or different cardiokines being induced by MI or 
PO.  
In order to recapitulate the human metabolic heart disease in a controlled and 
relevant setting of obesity and diabetes, WT mice were fed a  “Western diet”. Mice fed 
with this high-fat high-sucrose (HFHS) diet, containing 35.5% fat (lard) and 36.3% 
carbohydrate, for 8 months exhibited myocardial hypertrophy, impaired relaxation, 
preserved ejection fraction, and fibrosis (93).  
Based on this information, the goal of this study is to identify the early fibrotic 
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cardiokines responsible for cardiac fibrosis in a diet feeding mouse model of MHD. So 
the fibrotic signaling and cardiokine identification results were derived from mice that 
were fed mice between 2 weeks and 4 months.  
3.2 Results and Discussion 
3.2.1 Diastolic dysfunction development in HFHS fed mice 
 Mice fed on HFHS diet began to gain significantly more weight compared to 
those on control diet starting at 3 months into the diet (Figure 7A). Left ventricular (LV) 
dimensions and systolic functions were measured by 2-dimentional and M-mode 
echocardiography. Left ventricular total wall thickness was increased after 2 months on 
HFHS diet, as shown in Figure 7B. Systolic function was preserved with HFHS feeding 
as shown in unchanged fractional shortening measurements, Figures 8 respectively. The 
diastolic functions measured by Doppler Echocardiography showed slowed early 
diastolic velocity (Em) by 3 months and decreased early to late filling velocity ratio (E/A) 
by 4 month on HFHS diet compared to control diet, as shown in Figure 9A and B. Taken 
together, HFHS fed mice recapitulate critical aspects of human MHD with respect to 
cardiac hypertrophy, preserved systolic function, and impaired diastolic function. It is 
also important to note that diastolic dysfunction became detectable between 3-4 months 
on HFHS diet, most likely due to the slow accumulation of cardiac fibrosis which has 
been reported to correlated with increasing severity of diastolic function (16). 
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Figure 7 Mice fed HFHS develop cardiac hypertrophy. 
Male C57BL/6 mice fed HFHS diet or calorically-matched control diet for 1 to 8 months. 
Periodic body weight was recorded and total wall thickening was measured by 
echocardiography. All values represent mean ± standard error, n=3-4, *p<0.05 vs. CD. 
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Figure 8 Mice fed HFHS diet have preserved systolic function. 
Male C57BL/6 mice fed HFHS diet or calorically-matched control diet for 1 to 8 months. 
Myocardial systolic functions was measured by fractional shortening (FS) by M-mode 
echocardiography. All values represent mean ± standard error, n=3-4, *p<0.05 vs. CD.  
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Figure 9 HFHS diet induces diastolic dysfunction. 
Male C57BL/6 mice fed HFHS diet or calorically-matched control diet for 1 to 8 months. 
Diastolic myocardial functions were attained by Doppler echocardiogram measuring 
early diastolic velocity, Em, and early-to-late diastolic velocity ratio, E/A. All values 
represent mean ± standard error, n=3-4, *p<0.05 vs. CD.  
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3.2.2 Interstitial fibrosis induced by HFHS diet 
 Our lab has previously published that at 8 months on HFHS diet cardiac fibrosis is 
present (93). However, given that this goal of this project is to study the diet model of 
MHD before the secondary perturbations such as glucose intolerance, kidney failure, and 
liver failure begin after 4 months on HFHS diet, it is necessary to determine whether 
cardiac interstitial fibrosis is present at the end-point of this study. Mice fed HFHS or 
control diet for 2 months and 4 months were used to examine their relative cardiac 
interstitial fibrosis using histological staining of left ventricular tissue sections. 
Picrosirius red staining was used to measure relative fibrotic remodeling in LV tissue 
sections (103). Histological analysis showed ~2-fold increase in mice fed HFHS diet for 
4 months but insignificant change in fibrosis at 2 months on diet (Figures 10 and 11). 
This aligns with the development of significant deterioration in diastolic function at some 
time point after 2 months and before or at 4 months on diet. Although this cannot 
establish causation between fibrosis and diastolic dysfunction, it does suggest that a 
threshold of fibrotic accumulation needs to be reached prior to diastolic function being 
affected in a meaningful way.  
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Figure 10 Interstitial fibrosis in 2-months HFHS fed mice. 
 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 2 months. 
A portion of the left ventricular free wall was formalin fixed and paraffin embedded. 
Paraffin sections (4 µm) were stained with picrosirius red for detection of fibrosis. 
Images were analyzed with Image J. All values represent mean ± standard error, n=3; n.s. 
vs CD. Bar indicates 50 µm. 
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Figure 11 Interstitial fibrosis in 4-months HFHS fed mice. 
 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 4 months. 
A portion of the left ventricular free wall was formalin fixed and paraffin embedded. 
Paraffin sections (4 µm) were stained with picrosirius red for detection of fibrosis. 
Images were analyzed with Image J. All values represent mean ± standard error, n=3; 
*p<0.05 vs CD. Bar indicates 50 µm. 
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3.2.3 Early fibrotic gene regulation induced by HFHS feeding 
 The mRNA expressions of fibrotic genes that contribute to the overall fibrotic 
remodeling of the ECM were measured by quantitative RT-PCR. Collagen I and III, the 
two predominant types of collagen found in the heart, were significantly induced. 
Collagen I pro-collagen is formed inside the cell from two alpha 1 chains and one alpha 2 
while collagen III pro-collagen is formed with a triple helix of the same three alpha 1 
chains (104). Both alpha 1 and alpha 2 chains expressions are regulated at the 
transcriptional level. Shown in Figure 12, Col1a2 mRNA was significantly increased by 
65% at 2 weeks, 52% at 1 month, 74% at 2 months on HFHS diet feeding compared to 
control mice. Additionally, Col3a1 mRNA was increased by 81% at 2 weeks, 53% at 1 
month, and 73% at 2 months on HFHS diet feeding compared to control diet fed mice as 
shown in Figure 13. Matrix metalloproteinase (MMP) mRNA remained unchanged 
between HFHS and control diet fed mice, with only a 30% decrease in Mmp13 at 2 
months on diet (Figure 14). Conversely, tissue inhibitors of MMPs (TIMPs) were 
upregulated in HFHS-fed mice. Expression of Timp1 increased by 67% at 1 month on 
HFHS diet compared to control (Figure 15).  
The overall fibrotic transcriptional activation support the hypothesis that the 
fibrotic phase of the remodeling takes place soon after the diet starts and is only actively 
upregulated prior to the detection of pathological phenotypes. Notice that at the 
transcriptional level, collagens, MMPs, and TIMPs gene expressions either become or 
remain the same between those fed HFHS diet or control diet at 4 months. Seeing the 
regulation of ECM genes being modulated so soon after being put on a metabolic diet  
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Figure 12 Collagen I mRNA was significantly induced by HFHS feeding. 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 2 weeks to 
4 months. RNA isolated from left ventricular tissue and the level of collagen I alpha 2 
isoform, Col1a2, mRNA expressions was analyzed with quantitative RT-PCR and 
normalized to Gapdh levels. All values represent mean ± standard error, n=4, *p<0.05 vs. 
control diet. 
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Figure 13 Collagen III mRNA was significantly induced by HFHS feeding 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 2 weeks to 
4 months. RNA isolated from left ventricular tissue and the level of collagen III alpha 1 
isoform, Col3a1, mRNA expression was analyzed with quantitative RT-PCR and 
normalized to Gapdh levels. All values represent mean ± standard error, n=4, *p<0.05, 
**p<0.01 vs. control diet. 
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Figure 14 Mmp mRNA was unchanged by HFHS diet. 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 2 weeks to 
4 months. RNA isolated from left ventricular tissue and the mRNA expressions of tissue 
metalloproteinases Mmp3, Mmp9, and Mmp13 were analyzed with quantitative RT-PCR 
and normalized to Gapdh levels. All values represent mean ± standard error, n=4, 
*p<0.05 vs. control diet. 
0.5 1 2 4
0.0
0.5
1.0
1.5
2.0
2.5
Months on Diet
R
el
at
iv
e
m
R
N
A
 E
xp
re
ss
io
n 
Mmp9 mRNA
Control diet HFHS diet
Values are Mean ± SEM, n=4
Statistical analysis using Student t-test
* p<0.05, **p<0.01 vs. CD
n.s. n.s.
n.s.
n.s.
0.5 1 2 4
0.0
0.5
1.0
1.5
2.0
2.5
Months on Diet
R
el
at
iv
e
m
R
N
A
 E
xp
re
ss
io
n 
Mmp13 mRNA
CD diet HFHS diet
Values are Mean ± SEM, n=4
Statistical analysis using Student t-test
* p<0.05, **p<0.01 vs. CD
n.s.
n.s.
* n.s.
  55 
55 
  
 
 
Figure 15 Timp mRNA was elevated by HFHS diet feeding. 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 2 weeks to 
4 months. RNA isolated from left ventricular tissue and the mRNA expressions of tissue 
inhibitor of metalloproteinases Timp1 and Timp3 were analyzed with quantitative RT-
PCR and normalized to Gapdh levels. All values represent mean ± standard error, n=4, 
*p<0.05, **p<0.01 vs. control diet. 
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begs the question of how this compare in human obesity and whether fibrosis can be 
reversed if the mice were to be taken off the diet.  
3.2.4 Increased profibrotic factors in the heart 
  Cardiokines transforming growth factor-β1 (TGF-β1), angiotensin II (Ang II), 
and endothelin-1 (ET-1) have been reported to be upregulated in various models of heart 
failure, and correlated with increased cardiac fibrosis (105-107). To evaluate the roles of 
these pathways in fibrosis generated by HFHS diet feeding, mRNA expressions of Tgf-
β1, precursor of angiotensin II, Agt, and Edn were in RNA samples isolated from the left 
ventricular (LV) tissue. While Tgf-β1 mRNA was significantly increased by 3.6-fold at 2 
weeks and 4.1-fold at 1 month on HFHS diet compared to normal control detected by 
quantitative RT-PCR, as shown in Figure 16. Immunoblotting for Tgf-β1 in HFHS-fed 
mouse hearts showed the latent isoform increased by 4.8-fold and mature isoform 
increased by 3.8-fold, as depicted in Figure 17. Cardiac derived mRNA expression of 
Agt was not significantly upregulated by HFHS diet, though the values trended up 
(Figure 18A). Similarly, Edn mRNA levels were also unaffected by HFHS diet 
compared to control diet feeding as shown in Figure 18B.  
Clearly evident from these findings is that TGF-β1 is likely the driving profibrotic 
cardiokine that is responsible for the fibrotic activation. What is interesting to note is the 
immediate upregulation of Tgf-β1 mRNA just 2 weeks after being put on diet, similar to 
Col, Mmp, and Timp mRNA expressions. However, the increased synthesis drops off 
after 1 months on HFHS diet compared to control, well before fibrotic gene regulations  
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Figure 16 Tgf-β1 mRNA upregulated with HFHS feeding 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 2 weeks to 
4 months. RNA isolated from left ventricular tissue and the level of Tgf- β1 mRNA 
expression was analyzed with quantitative RT-PCR and normalized to Gapdh levels. All 
values represent mean ± standard error, n=4, *p<0.05 vs. control diet. 
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Figure 17 TGF-β1 protein induced by HFHS diet 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 1 month. 
Proteins isolated from left ventricular tissue lysates were immunoblotted for TGF-β1 and 
normalized to levels of GAPDH. All values represent mean ± standard error, n=4, 
*p<0.05 vs. control diet. 
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Figure 18 Angiotensinogen and endothelin-1 mRNA levels were unchanged by 
HFHS diet. 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 1 month. 
RNA isolated from left ventricular tissue and the level of Agt and Edn mRNA 
expressions were analyzed with quantitative RT-PCR and normalized to Gapdh levels. 
All values represent mean ± standard error, n=4, n.s. vs. control diet. 
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plateau and detectable fibrosis appear. One explanation for this phenomenon is that the 
ECM acts as a storage for latent signaling proteins including TGF-β1 (22). The actual 
concentration of biologically active TGF-β1 needed to activate intracellular signaling is 
very small. Therefore, even without active transcriptional upregulation of Tgf-β1 after 2 
months on diet there is likely enough latent TGF-β1 stored up in the ECM to mediate 
fibrosis. 
In addition to the prevalent profibrotic paracrine factors that were probed earlier, 
Tgf-β2 and Fstl3 were also of interest since Tgf-β2 expression is also induced in early 
post-MI response in the infarct area (66) and Fstl3 has been suggested as a cardiac 
myocyte secreted profibrotic factor (61). Tgf-β2 mRNA expression increased by 1.6-fold 
at 2 weeks, 1.5-fold at 1 month, 2.2-fold at 2 months, and unchanged at 4 months on 
HFHS diet compared to control diet fed animals (Figure 19). The TGF-β2 protein level 
also increased 2-fold in 1-month HFHS diet fed animals as detected by immunoblotting 
and shown in Figure 20. As was hypothesized, Fstl3 mRNA expression also increased 
with HFHS diet by 22% at 2 weeks, 41% by 1 month, 37% by 2 months and unchanged 
by 4 months as depicted in Figure 21. Protein expression of FSTL3 was similarly 
increased by 65% in left ventricular tissue lysates (Figure 22).  
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Figure 19 Tgf-β2 mRNA was significantly induced by HFHS feeding 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 2 weeks to 
4 months. RNA isolated from left ventricular tissue and the level of Tgf- β1 mRNA 
expression was analyzed with quantitative RT-PCR and normalized to Gapdh levels. All 
values represent mean ± standard error, n=4, *p<0.05 vs. control diet. 
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Figure 20 TGF-β2 protein levels increased with HFHS diet 
Immunoblotting for TGF-β2 protein expression in LV lysates detected increases with 1 
month of HFHS diet feeding. All values represent mean ± standard error, n=4, *p<0.05 
vs. control diet. 
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Figure 21 Fstl3 mRNA level increased with HFHS feeding 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 2 weeks to 
4 months. RNA isolated from left ventricular tissue and the level of Fstl3 mRNA 
expression was analyzed with quantitative RT-PCR and normalized to Gapdh levels. All 
values represent mean ± standard error, n=4, *p<0.05 vs. control diet. 
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Figure 22 FSTL3 protein level was upregulated in HFHS fed mice. 
C57BL/6 mice were fed a HFHS diet or a calorically matched control diet for 1 month. 
Proteins isolated from left ventricular tissue lysates were immunoblotted for FSTL3 and 
normalized to levels of GAPDH. All values represent mean ± standard error, n=4, 
*p<0.05 vs. control diet. 
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3.2.5 Cardiokines are induced in the cardiac myocytes and non-myocytes 
 To identify whether the cardiokines that were induced at the whole heart level 
were contributed by cardiomyocytes, mouse hearts were enzymatically digested and 
separated into myocyte and non-myocyte fractions. The non-myocyte fraction is 
composed of predominantly cardiac fibroblasts, endothelial cells, and vascular smooth 
muscle cells. RNA isolated directly from the myocyte and non-myocyte fractions 
provided insight to which cell types were primarily responsible for each cardiokine.  
First, to verify that the myocyte fraction did not contain significant fibroblast 
contamination using this method, the use of quantitative RT-PCR was applied to detect 
the mRNA expression of Col1a2 and Col3a1 that are predominantly produced by 
fibroblasts. As expected, myocyte fraction expression of Col1a2 was not upregulated in 
the HFHS-fed mice whereas non-fibroblast fraction isolated from HFHS fed mice was 
significantly increased by 2-fold (Figure 23). Similarly, Col3a1 was also unchanged in 
the myocyte fractions but increased by 2-fold in non-myocyte fractions isolated from 1 
month HFHS-fed mice (Figure 24). This result indicates that the myocyte fraction has 
little fibroblast contamination to allow us to confidently use it as a source to test myocyte 
derived cardiokine expressions. 
Next, using the verified myocyte and non-myocyte fraction the hypothesis that 
cardiomyocytes is the source of cardiokines identified earlier – TGF-β1, TGF-β2, and 
FSTL3. Tgf-β1 mRNA expression was upregulated by 85% in HFHS non-myocyte 
fraction but unchanged in myocyte fraction (Figure 25).  
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Figure 23 Col1a2 expression increased in non-myocyte fractions of HFHS-fed 
animals. 
Cardiac myocytes and non-myocytes were isolated from C57BL/6 mice that were fed a 
HFHS diet or a calorically matched control diet for 1 month. RNA isolated from the 
myocyte and non-myocyte fractions were probed for the expression of Col1a2 using 
qRT-PCR and normalized to the expression of Gapdh. All values represent mean ± 
standard error, n=3, n.s. vs. control diet. 
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Figure 24 Col3a1 increased in non-myocyte fractions of HFHS animals. 
Cardiac myocytes and non-myocytes were isolated from C57BL/6 mice that were fed a 
HFHS diet or a calorically matched control diet for 1 month. RNA isolated from the 
myocyte and non-myocyte fractions were probed for the expression of Col3a1 using 
qRT-PCR and normalized to the expression of Gapdh. All values represent mean ± 
standard error, n=3, *p<0.05 vs. control diet. 
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Figure 25 Tgf-β1 mRNA expression induced in the non-myocyte fraction with HFHS 
feeding. 
Cardiac myocytes and non-myocytes were isolated from C57BL/6 mice that were fed a 
HFHS diet or a calorically matched control diet for 1 month. RNA isolated from both cell 
fractions were probed for the expression of Tgf-β1 using qRT-PCR and normalized to the 
expression of Gapdh. All values represent mean ± standard error, n=3, *p<0.05 vs. 
control diet. 
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Similarly, Tgf-β2 mRNA expression was also upregulated in the HFHS non-myocyte 
fraction by 76% but unchanged in the myocyte fraction, as illustrated in Figure 26. 
Though contrary to our hypothesis both Tgf-β1 and Tgf-β2 were upregulated in the non-
myocytes, they should still be considered as MHD induced cardiokines, protein secreted 
from the heart. Given that most cells can synthesize TGF-β secreted proteins (57) and 
have TGF-β receptors on their cell membranes, it is likely that the cardiac fibroblasts 
and/or endothelial cells responsible are primarily responsible for the increased synthesis 
of Tgf-β1 and Tgf-β2 observed in the non-myocyte fractions with HFHS diet feeding. In 
contrast, Fstl3 mRNA expression in myocytes isolated from HFHS fed mice was 
increased by 30% but unchanged in the non-myocyte fraction, as shown in Figure 27.  
3.2.6 TGF-β1 and TGF-β2 activate profibrotic signaling in vitro while Fstl3 does not 
 To test the profibrotic actions of the identified cardiokines, in vitro culture with 
primary adult rat ventricular fibroblasts (ARVFs) and the NIH 3T3 fibroblasts cell line 
were used. Only first to third passage of ARVFs were used for the in vitro experiments. 
Cells were starved overnight before they were incubated in experimental media 
containing recombinant human TGF-β1 (10 ng/mL) or TGF-β2 (10 ng/mL) or FSTL3 (10 
ng/mL) for 30 minutes to detected phosphorylation events of the profibrotic pathway.  
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Figure 26 Tgf-β2 mRNA expression was induced in the non-myocyte fraction with 
HFHS feeding. 
Cardiac myocytes and non-myocytes were isolated from C57BL/6 mice that were fed a 
HFHS diet or a calorically matched control diet for 1 month. RNA isolated from both cell 
fractions were probed for the expression of Tgf-β2 using qRT-PCR and normalized to the 
expression of Gapdh. All values represent mean ± standard error, n=3, *p<0.05 vs. 
control diet. 
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Figure 27 Fstl3 mRNA expression increased with HFHS feeding in the myocyte 
fraction. 
Cardiac myocytes and non-myocytes were isolated from C57BL/6 mice that were fed a 
HFHS diet or a calorically matched control diet for 1 month. RNA isolated from both cell 
fractions were probed for the expression of Fstl3 using qRT-PCR and normalized to the 
expression of Gapdh. All values represent mean ± standard error, n=4-5, *p<0.05 vs. 
control diet. 
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The 30-minute treatment was based on a time-course test with the positive control TGF-
β1 treatment that gave the strongest phosphorylation of the canonical SMAD2/3 pathway. 
Accordingly, ARVFs treated with TGF-β2 activated phosphorylation of SMAD2/3 by 4-
fold compared to control, whereas TGF-β1 increased SMAD2/3 phosphorylation by 3.4-
fold and FSTL3 did not activate phosphorylation of SMAD2/3 as shown in Figure 28. 
Cross-activation of SMAD1/5/8 has been known to occur with TGF-β signaling. Thus, it 
was not surprising to see SMAD1/5/8 phosphorylation increase by 1.7-fold with TGF-β1 
(p=0.07) and 3-fold with TGF-β2 treatment, but FSTL3 did not activate SMAD1/5/8 as 
shown in Figure 29. Non-canonical TGF-β signaling includes ERK1/2 phosphorylation, 
which was not induced in this experiment (Figure 30). So far, in ARVFs only TGF-β2 
and the positive control TGF-β1 activated the profibrotic SMAD signaling pathway while 
FSTL3 did not. Thus, to be absolutely sure FSTL3 does not utilize canonical SMAD 
signaling or alternative TGF-β signaling pathways to activate cultured fibroblasts, NIH 
3T3 mouse embryonic fibroblast cell line was used to remove any variability with 
primary cell that could have affected the activity of FSTL3 recombinant protein.  
NIH3T3 is an immortalized mouse embryonic fibroblast cell line, widely used to 
test fibrotic signaling events in vitro (108). Similar to ARVFs, subconfluent 3T3 
fibroblasts were serum-starved overnight before incubation with experimental media 
containing recombinant human FSTL3 (20 ng/mL) or TGF-β2 (20 ng/mL) for 30 
minutes. Compared to vehicle control conditions, FSTL3 treatment did not activate 
SMAD2/3  
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Figure 28 Phosphorylation of SMAD2/3 by TGF-β2 but not FSTL3 in ARVF. 
ARVF cell cultures were treated with recombinant human TGF-β1, TGF-β2, or FSTL3 
proteins (10 ng/mL) or vehicle control for 30 minutes. Phosphorylated SMAD2/3 was 
immunoblotted and normalized to total SMAD2/3 levels. . All values represent mean ± 
standard error, n=3, **p<0.01 or n.s. vs. control, δδ p<0.01 vs. FSTL3 treated (ANOVA 
with Bonferoni post-test). 
Ctrl TGF-β1 TGF-β2 FSTL3 
Recombinant Protein 
(10 ng/mL) 
phospho-SMAD2/3 
total-SMAD2/3 
SMAD2/3
Control TGF-β1 TGF-β2 FSTL3
0.0
0.5
1.0
1.5
2.0
2.5
ph
os
ph
o/
to
ta
l S
m
ad
2/
3
Recombinant Protein Treatment (10 ng/mL)
**, δδ
δδ  p<0.01 vs Fstl3
**  p<0.01 vs Ctrl
n.s.
**, δδ
Values are Mean ±SEM, n=3
Student t-test
  74 
74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 Phosphorylation of SMAD1/5/8 by TGF-β2 but not FSTL3 in ARVF. 
ARVF cell cultures were treated with recombinant human TGF-β1, TGF-β2, or FSTL3 
proteins (10 ng/mL) or vehicle control for 30 minutes. Phosphorylated SMAD1/5/8 was 
immunoblotted and normalized to total SMAD1/5/8 levels. . All values represent mean ± 
standard error, n=3, *p<0.05 or n.s. vs. control, δ p<0.05 vs. FSTL3 treated (ANOVA 
with Bonferoni post-test). 
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Figure 30 ERK1/2 was not phosphorylated by TGF-β or FSTL3 in ARVF. 
ARVF cell cultures were treated with recombinant human TGF-β1, TGF-β2, or FSTL3 
proteins (10 ng/mL) or vehicle control for 30 minutes. Phosphorylated ERK was 
immunoblotted and normalized to total ERK levels. . All values represent mean ± 
standard error, n=3, n.s. vs. control (ANOVA with Bonferoni post-test). 
 
Ctrl TGFβ-1 TGFβ-2 FSTL3 
Recombinant Protein 
10 ng/mL 
phospho-ERK 
total-ERK 
ERK Protein
Control TGF-β1 TGF-β2 FSTL3
0.0
0.5
1.0
1.5
2.0
ph
os
ph
o 
/to
ta
l E
R
K
Recombinant Protein Treatment (10 ng/mL)
n.s.
n.s.n.s.
  76 
76 
phosphorylation whereas TGF-β2 increased SMAD2/3 phosphorylation by 2.8-fold 
(Figure 31). Shown in Figure 32, neither TGF-β2 nor FSTL3 activated SMAD1/5/8 
signaling in 3T3 cells. Of the alternative TGF-β signaling pathways, only p-38 was 
minimally activated by TGF-β2 (Figure 33). To determine whether FSTL3 activates 
other alternative profibrotic signaling pathways in 3T3 cells, TGF-β1 was again used as 
positive control. As shown in Figure 34 and 35, neither TGF-β1 nor FSTL3 activated the 
c-Jun N-terminal kinase (JNK) or myosin phosphatase target subunit 1 (MYPT1). 
Together, these results suggest that FSTL3 does not activate the downstream TGF-β 
signaling pathways but TGF-β2 does activate the known signaling pathways.  
3.2.7 Collagen synthesis is induced by TGF-β2 
 In order to test the profibrotic effect each cardiokine has on collagen synthesis, 
cultured ARVMs and 3T3 fibroblasts were once again treated with recombinant proteins. 
First, the Col1a2 and Col3a1 mRNA expressions were utilized as an indicator of collagen 
synthesis in ARVFs treated with recombinant TGF-β1, TGF-β2 or FSTL3 (10 ng/mL) for 
24 hours. However, collagen mRNA was not induced even by the positive control 
treatment of TGF-β1. This lack of collagen mRNA signal initiated a series of 
troubleshooting events geared to optimize culturing of primary ARVFs. Rather than using 
0% FBS DMEM as the baseline culturing media, sequential additions of FBS starting 
from 0.4% to 10% FBS was used without any change in the observed effect on collagen 
mRNA. Next, a time course experiment was conducted by collecting ARVMs 12, 16, 24, 
and 48 hours after recombinant protein treatment. Once again, no difference was 
observed in the relative expression of Col1a2 mRNA in the positive controls (TGF-β1 
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Figure 31 TGF-β2 activated SMAD2/3 in 3T3 fibroblasts. 
3T3 fibroblast cultures were treated with recombinant human TGF-β2, FSTL3 proteins 
(10 ng/mL) or vehicle control for 30 minutes. Phosphorylated SMAD2/3 was 
immunoblotted and normalized to total SMAD2/3 levels. . All values represent mean ± 
standard error, n=3, ****p<0.0001 or n.s. vs. control, δδδδ p<0.0001 vs. FSTL3 treated 
(ANOVA with Bonferoni post-test).  
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Figure 32 SMAD1/5/8 was not activated in 3T3 fibroblasts treated with FSTL3 or 
TGF-β2. 
3T3 fibroblast cultures were treated with recombinant human TGF-β2, FSTL3 proteins 
(10 ng/mL) or vehicle control for 30 minutes. Phosphorylated SMAD1/5/8 was 
immunoblotted and normalized to total SMAD1/5/8 levels. . All values represent mean ± 
standard error, n=3, n.s. vs. control (ANOVA with Bonferoni post-test). 
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Figure 33 Phosphorylation of p38 by TGF-β1 but not FSTL3 in 3T3 fibroblasts. 
3T3 fibroblast cultures were treated with recombinant human TGF-β1 or FSTL3 proteins 
(10 ng/mL) or vehicle control for 30 minutes. Phosphorylated ERK was immunoblotted 
and normalized to total ERK levels. . All values represent mean ± standard error, n=3, 
*p<0.05 or n.s. vs. control (ANOVA with Bonferoni post-test). 
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Figure 34 JNK was not activated in 3T3 fibroblasts treated with FSTL3 or TGF-β1. 
3T3 fibroblasts cultures were treated with recombinant human TGF-β1 or FSTL3 
proteins (10 ng/mL) or vehicle control for 30 minutes. Phosphorylated JNK was 
immunoblotted and normalized to total JNK levels. All values represent mean ± standard 
error, n=3, n.s. vs. control (ANOVA with Bonferoni post-test). 
phospho-JNK 
Co
ntr
ol 
rF
ST
L3
 
rT
GF
-β1
 
total-JNK 
Recombinant Protein 
20 ng/mL 
CTRL FSTL3 TGFB1
0.0
0.5
1.0
1.5
JNK
Ph
os
ph
o/
To
ta
l J
N
K
n.s. n.s.
  81 
81 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35 MYPT1 was not activated in 3T3 fibroblasts treated with FSTL3 or TGF-
β1. 
3T3 fibroblast cultures were treated with recombinant human TGF-β1, TGF-β2, or 
FSTL3 proteins (10 ng/mL) or vehicle control for 30 minutes. Phosphorylated MYPT1 
was immunoblotted and normalized to total MYPT1levels. All values represent mean ± 
standard error, n=3, n.s. vs. control (ANOVA with Bonferoni post-test) 
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and Angiotensin II), TGF-β2 or FSTL3. Finally, as an alternative to using recombinant 
proteins ARVMs were infected with Adv-Fstl3 or Adv-LacZ for 48 hours and the ARVM 
conditioned media was placed onto cultured 3T3 cells for a further 24 hours. RNA 
collected from 3T3 cells show no different in Col1a2 and Col3a1, as shown in Figure 36. 
After exhausting various methods to activate collagen mRNA expression in cultured 
fibroblasts, it was no longer a viable readout that could be used in vitro for collagen 
synthesis. The difference in vitro and in vivo is something that cannot be discounted, 
especially since cultured fibroblasts must be able to attach to plastic culturing dishes 
rather than inhabiting in their native interstitial space. 
 Moving forward, efforts were focused on detecting collagen protein synthesis in 
vitro. As expected, TGF-β2 treatment increased collagen III protein levels by 87% while 
FSTL3 had no effect on collagen III protein synthesis in 3T3 fibroblasts (Figure 37). 
This data together with the earlier signaling data indicate that TGF-β2 is a profibrotic 
cardiokine while there is no evidence to support FSTL3 as a profibrotic cardiokine. 
Although FSTL3 does not appear to be profibrotic, it is still a secreted protein of interest 
due to its induction in the cardiomyocytes by HFHS diet feeding and elevated myocardial 
expression and plasma levels in end-stage heart failure patients (92). 
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Figure 36 Conditioned media from Adv-Fstl3 infected ARVM did not activate 
collagen mRNA expression in 3T3 fibroblasts. 
Cultured 3T3 fibroblasts were treated for 24 hours with conditioned media (CM) from 
ARVMs infected with Adv-Fstl3 or Adv-LacZ control for 48 hours. RNA isolated from 
3T3 cells were probed for gene expression of Col1a2 and Col3a1 with qRT-PCR and 
normalized to Gapdh expression levels. All values represent mean ± standard error, n=4, 
n.s. vs. control. 
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Figure 37 Collagen III protein was induced by TGF-β2 but not FSTL3 in 3T3 
fibroblasts. 
3T3 fibroblasts cultures were treated with recombinant human TGF-β1, TGF-β2, or 
FSTL3 proteins (20 ng/mL) or vehicle control for 24 hours. Cell lysates were 
immunoblotted for collagen III expression and normalized to GAPDH levels. All values 
represent mean ± standard error, n=3, *p<0.5,  δδδ p<0.001 vs. control (ANOVA with 
Bonferoni post-test). 
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3.2.8 Metabolic syndrome patient samples have increased Follistatin-like 3 
 Concurrent with the mouse studies of cardiokines induced MHD, clinical data was 
also collected from patients diagnosed with metabolic syndrome, the criteria for 
metabolic syndrome patient enrollment is outlined in detail in the Methods Section. 
Plasma samples collected from patients with metabolic syndrome and healthy donors. 
Measurements of left ventricular mass normalized by height, LVH_ht, and mitral annular 
myocardial diastolic velocity, Em, were obtained. Metabolic syndrome patient recruits 
can be further divided into four groups according to tertiles of LVH_ht and Em. LVH_ht 
was higher and Em was lower in subjects with metabolic syndrome compared to controls. 
 To analyze the plasma concentrations FSTL3 in the patient samples, a sandwich 
ELISA kit specific for human FSTL3 was used. FSTL3 was significantly increased in the 
metabolic syndrome patients (6488±1905 pg/mL) compared to controls (4936±1085 
pg/mL). Of the four sub-categories of Metabolic Syndrome samples, FSTL3 was 
significantly increased in the group with the lowest Em and highest LVH_ht (worst 
echocardiographic parameters) with 7230±2339 pg/mL (Table 4). Increasing FSTL3 was 
correlated with decreasing Em (r2=0.13, p=0.002) calculated by univariate linear 
regression (Figure 38). Increasing FSTL3 was correlated with increasing LVH_ht 
(r2=0.13, p=0.002) determined by univariate regression (Figure 39). FSTL3 also 
positively correlated strongly with age (data not shown). Though not significant, FSTL3 
trends positively with hypertension and diabetes (data not shown). Together, this data  
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Table 4 Metabolic syndrome patient statistics. 
Metabolic syndrome patients and healthy control were examined for their diastolic function (Em), hypertrophy (LV 
mass/height) and plasma Fstl3. Control donors n=14 and total Metabolic syndrome patients included 63.  * p≤0.001; # p<0.01; 
€ p=0.05 vs highest Em/lowest LV group. 
 
Parameter Controls 
N=14 
MetS 
(total) 
N=63 
Highest 
Em/Lowest 
LVmass/ht 
N=16 
Highest 
Em/Highest 
LVmass/ht 
N=9 
Lowest 
Em/Lowest 
LVmass/ht 
N=12 
Lowest 
Em/Highest 
LVmass/ht 
N=26 
Gender 6M, 8F 18M, 45F 4M, 12F 3M, 6F 5M, 7F 6M, 20F 
Em 13.5±2.4 9±2.8* 12.2±1.9 11.7±1.6 7.1±1.1* 7±0.7* 
LVmass/ht 26.6±4 41.8±12.6* 30.6±4 48.3±4.4* 29.9±4.4 52±9.9* 
FLRG, pg/ml 4936±1085 6488±1905
# 5672±1402 6556±1462 5917±1072 7230±2339*,€ 
86 
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Figure 38 Plasma FSTL3 correlates with decreasing diastolic function. 
Scatter plot of plasma FSTL3 to Em in all patient samples. There is a negative correlation 
between FSTL3 and Em (r2=0.13, p=0.002) as calculated by SPSS using linear 
regression. 
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Figure 39 Plasma FSTL3 correlates with increasing cardiac hypertrophy. 
Scatter plot of plasma FSTL3 to Em in all patient samples. There is a positive correlation 
between FSTL3 and LVH_height (r2=0.13, p=0.002) as calculated by SPSS using linear 
regression. 
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Figure 40 Increased plasma FSTL3 levels in MetS patients with LV hypertrophy.  
Recruited patients were divided into three groups, healthy control, MetS with normal 
LVmass_ht, MetS with high LVmass_ht (LV hypertrophy). Their respective plasma 
FSTL3 and NT-pro-BNP levels were plotted. Statisticaly significance was calculated 
with One-way ANOVA with Bonferoi post-test. *p<0.05 vs MetS low LVmass_ht, 
***p<0.001 vs healthy controls. 
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Figure 41 Increased plasma FSTL3 levels in MetS patients with diastolic 
dysfunction. 
Recruited patients were divided into three groups, healthy control, MetS with normal Em, 
MetS with low Em (diastolic dysfunction). Their respective plasma FSTL3 and NT-pro-
BNP levels were plotted. Statisticaly significance was calculated with One-way ANOVA 
with Bonferoi post-test. n.s. vs MetS high Em, **p<0.01 vs healthy controls. 
 
FSTL3 NT-pro-BNP
0
5000
10000
15000
0
5000
10000
15000
Pl
as
m
a 
FS
TL
3 
(p
g/
m
L)
Em
Healthy Control
Low LVmass MetS
High LVmass MetS
**
n.s.
n.s.
n.s. n.s.
n.s.
Plasm
a N
T-pro-B
N
P (pm
ol/L)
  91 
91 
 
suggests the value of FSTL3 as a biomarkers of MHD. Considering human variability, 
the r2=0.13 as a predictor of Em and LVH_ht is a reasonable biomarker, though it cannot 
explain all the variability. Looking at the mean values of plasma FSTL3 levels in healthy, 
MetS with normal LVmass, and MetS with high LVmass, there was a significant 
elevation of plasma FSTL3 in the last group (Figure 40). Similarly, the mean values of 
plasma FSTL3 levels in healthy, MetS with normal diastolic function, and MetS with 
impaired diastolic function showed a significant increase in the last group as well (Figure 
41). In contrast, the gold standard biomarker (53) of LV hypertrophy NT-pro-BNP (more 
bioactively stable form of active BNP) was unchanged between the three groups, whether 
organized by LVmass or Em (Figure 40 and 41). Together, this suggests that plasma 
FSTL3 could be a more relevant biomarker of LV hypertrophy in the setting of MHD.  
 
3.2.8 Cardiomyocyte-specific Fstl3 knockout fed HFHS diet 
 Although the data so far do not support FSTL3 as a profibrotic cardiokine, its 
induction in cardiacmyocytes due to HFHS feeding in addition to the clinical data 
implicate FSTL3 as a biomarker LV hypertrophy in the setting of MHD. Therefore, a 
cardiac myocyte ablation of Fstl3 gene (FSTL3 KO) was generated to test the hypothesis 
that in the absence of cardiac FSTL3 HFHS diet feeding induced LV hypertrophy, 
diastolic function, and/or fibrosis can be ameliorated. 
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Figure 42 Heart weights to body weight ratio of FSTL3 Knockout Mice fed HFHS 
diet for 1 month. 
Preliminary heart weight and body weight ratios of male FSTL3 KO mice fed HFHS or 
CD diet for 1 month. The littermate control, homozygous Fstl3 floxed no Cre, was also 
fed either HFHS or CD diet as controls. Non-parametric t-tests analysis was used to 
compare the littermate control mice fed on CD (n=3) and HFHS (n=4) diet, as well as 
littermate control mice compared to FSTL3 knockout mice on HFHS (n=5) diet. Graph 
represents mean and individual animal data point, n.s. vs respective controls.   
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 Once the cardiac specific FSTL3 KO and WT littermates reach 8 weeks of age, 
they will be put on the same HFHS diet or control diet for 4 months. This experiment is 
currently on-going and once the 4-months of dieting is completed, several MHD 
phenotypes will be examined: diastolic dysfunction, myocardial hypertrophy, and 
interstitial fibrosis. The role of Fstl3 in hypertrophy was implicated in the attenuated 
cardiac hypertrophy observed in FSTL3 KO mice subjected to transverse aortic 
constriction (TAC) and that Fstl3 knockdown inhibited phenylephrine induced 
hypertrophy in cultured cardiomyocytes (81). Based on these findings, the FSTL3 KO 
mice are expected to have attenuated cardiac hypertrophy when fed the metabolic diet 
compared to control diet. Preliminary data collected from FSTL3 KO and control 
littermate mice were fed HFHS diet for 1 month and heart weight/body weight ratio 
(HW/BW) was measured. Although the HW/BW was not significantly different between 
control and knockout mice fed 1 month of HFHS diet, there is a trend toward decreasing 
HW/BW in FSTL3 KO fed HFHS diet compared to WT littermates HFHS diet (Figure 
42). This trend suggests that the absence of FSTL3 attenuates cardiac hypertrophy. In 
order to obtain definitive answer it will take 3-4 months on HFHS diet before concrete 
results could be distinguished since it takes that amount of time for wild-type mice for 
diet-induced cardiac hypertrophy to fully develop.  
3.3 Conclusion 
 This study intended to identify profibrotic cardiokines induced by the HFHS 
feeding model of MHD. From the mRNA analysis, Tgf-β1, Tgf-β2, and Fstl3 were 
identified as cardiokines increased by 4-fold, 16-fold, and 1.4-fold with only one month 
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on the metabolic diet. Out of the three cardiokines identified, only TGF-β1 and TGF-β2 
have profibrotic activities implicated by SMAD2/3 activation and collagen III synthesis 
in cultured fibroblasts. The early induction of Tgf-β1 and Tgf-β2 mRNA coincided with 
the activation of fibrotic gene regulation. In addition, interstitial fibrosis was detected 
after 4 months on diet when Tgf-β1, Tgf-β2, and ECM genes activations have tapered off. 
On the other hand, FSTL3 was determined to not have a profibrotic effect in cultured 
fibroblasts. However, plasma FSTL3 was elevated in metabolic syndrome subjects 
correlating with increased worsening of LV mass and diastolic relaxation rate. This 
implicates FSTL3 as a potential biomarker for MHD. To further test the role of FSTL3 in 
MHD, cardiac FSTL3 knockout mice were generated and are being fed HFHS diet to 
determine the role of FSTL3 in cardiac hypertrophy, diastolic dysfunction, or fibrosis. 
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Chapter 4: Cardiokines are induced in the cardiomyocytes of a 
cardiac-specific lipid overload transgenic mouse model 
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4.1 Rationale 
 Metabolic syndrome results in marked alterations in the substrate for cardiac 
energy metabolism (109). Elevated circulating FFA is a hallmark of obesity and diabetes 
(110) leading to the ectopic lipid accumulation into the myocardium which can cause cell 
dysfunction or death. In a normal adult heart, oxidation of long chain fatty acids (LCFA) 
will account for ~60% of its total ATP production, while glucose, ketones, and lactate are 
responsible for the remainder (111). However in obese, diabetic, and insulin resistant 
conditions, myocardial fatty acid beta-oxidation rate is elevated in mice (112-115)and 
humans (116, 117). This increase in fatty acid beta-oxidation directly inhibits glucose 
oxidations (112-115) making free fatty acids (FFA) the main energy source for the 
diseased myocardium. 
 Several regulatory proteins are responsible for the intracellular uptake of LCFA 
into the cardiomyocytes (Figure 43). Long-chain acyl-CoA synthetase 1 (ACS1) 
enhances entry of LCFA by lowering the cytosolic FFA concentration by esterification of 
FFA to acyl-CoA (118). Fatty acid translocase (FAT/CD36) binds and concentrates FFA 
at the plasma membrane during times of low concentrations extracellular FFA (119). 
Fatty acid transport protein (FATP) is the primary protein responsible for LCFA uptake 
(120) in obesity. The FATP family has many isoforms and widely distributed amongst 
organ and cellular localization (121). FATP1 is the only isoform highly expressed in 
adipose tissue, and along with FATP6, in the heart (13). Hence, the importance of FATP1 
is implicated by its exclusivity to the two of the most metabolically active organs.  
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Figure 43 Intracellular uptake of long-chain fatty acids. 
Circulating free fatty acids are bound to albumin and triglycerides reside in lipoprotein. 
Long chain fatty acids (LCFA) are concentrated at the outer cell membrane by fatty acid 
translocase (CD36) to be transported into the cell via fatty acid transport proteins 
(FATP). Once inside the cell, long-chain acyl-CoA synthetase esterifies LCFAs into acyl 
CoA. Adapted from Stahl et al. 2001, Trends in Endocr Metab. 
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To better examine the role of FATP1 in the myocardium, Chiu et. al. generated a 
cardiomyocyte-specific overexpression of Fatp1 allele driven by the α-MHC promoter. 
The Fatp1 transgenic animals (FATP1) presented 8-fold increase in cardiac FATP1 
protein expression which led to a 4-fold increase in LCFA uptake, 2-fold increase in FFA 
accumulation, and 2-fold increase in palmitate oxidation (94). Physiologically, FATP1 
mice developed myocyte and LV hypertrophy, impaired diastolic function with preserved 
systolic function, and fibrosis at 3-4 months of age compared to wild-type (WT) control 
animals (94). The diastolic dysfunction was shown to be independent of intraceullar Ca2+ 
flux at the myocyte sarcomeric level (122). Consequently, these attributes make the 
FATP1 transgenic mouse a great model to study MHD in the absence of systemic 
perturbations that can have additional negative effects on the heart.  
The goal of this study was to identify profibrotic cardiokines responsible for 
cardiac specific FFA-overload induced fibrosis, which has yet to be reported. Since the 
FATP1 transgenic mouse captures important aspects of MHD that are relevant to this 
study, they were utilized to determine specific cardiokines induced in the cardiac 
myocytes and the underlying mechanism of the observed fibrotic remodeling.  
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4.2 Results and Discussion 
4.2.1 Diastolic dysfunction and interstitial fibrosis in 5-week-old FATP1 mice 
 In the original report of FATP1 transgenic mice (94), significant increase in the 
left ventricular (LV) mass and LV to body weight ratio was recorded for the transgenic 
animal compared to WT littermates. At 3 months of age, Chiu et. al. noted that FATP1 
transgenic animals developed impaired diastolic function and cardiac fibrosis. In a 
comparison of mouse to human lifespan, a 3-month old mouse is the equivalent of a 
mature human adult between 20-30 years old (123). In a five-week-old FATP1 transgenic 
mouse, the equivalent age of an adolescent human, it was observed that diastolic function 
as measured by Mitral Doppler echocardiography of E/A ratio was increased and systolic 
function was preserved as evidenced by unchanged fractional shortening (Figure 44). 
Establishing that the diastolic dysfunction is developed as early as 5 weeks, sooner than 
previously reported, suggests that it is likely fibrosis is also developed at this point of 
time given that myocardial fibrosis has been reported to correlated with the degree of 
diastolic dysfunction (16). Therefore, LV tissue taken from FATP1 and WT littermates 
were fixed and subjected to histological staining with picrosirius red to determine the 
relative level of interstitial fibrosis in this model. In Figure 45, it was observed that 
interstitial fibrosis was increased by ~3-fold in FATP1 mice compared to control 
samples. This confirmed the hypothesis that significant myocardial fibrosis was present 
when diastolic dysfunction was observed in 5-week-old FATP1 mice. Therefore, for the 
purpose of this study mice at 5 weeks of age were used.  
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Figure 44 Diastolic dysfunction in FATP1 transgenic mice. 
Five-week-old FATP1 and WT littermates were used. Systolic and diastolic myocardial 
functions were measured, FS and E/A ratio, respectively. Presence of LV hypertrophy 
was determined with anterior wall thickness, AWTd. All values represent mean ± 
standard error, n=3-4, *p<0.05 vs. WT littermates. 
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Figure 45 Interstitial fibrosis in FATP1 mice. 
FATP1 and WT littermates were used. A portion of the left ventricular free wall was 
formalin fixed and paraffin embedded. Paraffin sections (4 µm) were stained with 
picrosirius red for detection of fibrosis. Images were analyzed with Image J. All values 
represent mean ± standard error, n=3; p<0.05. vs WT littermates. Bar indicates 50 µm.
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Figure 46 Collagen I mRNA increased in FATP1 mice. 
FATP1 and WT littermates were utilized. The RNA isolated from the ventricular tissues 
were used and the transcriptional expression of Col1a1 and Col1a2 were analyzed with 
qRT-PCR and normalized to the expression of Gapdh. All values represent mean ± 
standard error, n=6, **p<0.01, ***p<0.001 vs. WT littermates. 
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Figure 47 Collagen III mRNA increased in FATP1 mice 
FATP1 and WT littermates were utilized. The RNA isolated from the ventricular tissues 
were used and the transcriptional expression of Col3a1 was analyzed with qRT-PCR  and 
normalized to the expression of Gapdh. All values represent mean ± standard error, n=6, 
** p<0.01 vs. WT littermates. 
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4.2.2 ECM gene remodeling in FATP1 mice 
In order to examine the gene regulation of ECM components, RNA was isolated 
from LV tissue of FATP1 and WT mice and relative gene expression was determined by 
quantitative RT-PCR. Collagen I composed of alpha 1, Col1a1, and alpha 2, Col1a2, 
subunits were increased by 76% and 30%, respectively, in the FATP1 mice compared to 
control (Figure 46). Collagen III, Col3a1, mRNA level was increased by 40% in the 
Fatp1 overexpressing mice over control as well (Figure 47). These two observations 
correlate with the earlier histological findings of increased interstitial fibrosis in FATP1 
animals detected by picrosirius red, which is a stain specific for collagen I and III fibers. 
The active transcriptional regulation of collagen suggests that myocardial fibrotic 
remodeling was still on-going. This contrasts the 4-months diet data where interstitial 
fibrosis was detectable but fibrotic gene regulation had plateaued. The discrepancy in the 
models could be attributable to the overall age of the animals, difference between lipid 
overload versus a diet containing high fat and high sucrose, and the ultimate severity of 
fibrosis developed in each model.  
 Upon further evaluation of other ECM components shown in Figure 48, it was 
determined that the basal lamina collagen IV (Col4a5) increased by 40%, elastin (Eln1) 
increased by 70%, fibrillin (Fbn1) increased by 30%, and fibronectin (Fb1) increased by 
50% in FATP1 transgenic mice compared to WT. The overall expression of key MMPs 
were decreased as shown in Figure 49, collagenase Mmp13 decreased by 80.4%, 
gelatinase Mmp8 decreased by 77%, and membrane-type Mmp14 was unchanged in  
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Figure 48 Elastin, Fibronetin, and Fibrillin increased with FATP1 overexpression. 
FATP1 and WT littermates were utilized. The RNA isolated from the ventricular tissues 
were used and the transcriptional expression of Col4a5, Eln, Fbn1, Fn1 were analyzed 
with qRT-PCR  and normalized to the expression of Gapdh. All values represent mean ± 
standard error, n=6, n.s. vs. WT littermates. 
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Figure 49 Mmp mRNA decreased with Fatp1 overexpression. 
FATP1 and WT littermates were utilized. The RNA isolated from the ventricular tissues 
were used and the transcriptional expression of Mmp9, Mmp13, and Mmp14 were 
analyzed with qRT-PCR and normalized to the expression of Gapdh. All values represent 
mean ± standard error, n=6, n.s. vs. WT littermates. 
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Figure 50 Timp1 mRNA increased with Fatp1 overexpression. 
FATP1 and WT littermates were utilized. The RNA isolated from the ventricular tissues 
were used and the transcriptional expression of Timp1 were analyzed with qRT-PCR and 
normalized to the expression of Gapdh. All values represent mean ± standard error, n=6, 
**p<0.01. vs. WT littermates. 
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FATP1 mice. Conversely, Timp1 mRNA expression was increased by 3.1-fold as shown 
in Figure 50. Taken together, the fibrotic remodeling in the FATP1 mice utilizes the 
transcriptional regulation of various ECM components in response to FFA overload in the 
myocardium. Since TGF-β1 is not induced in FATP1 myocardium to modulate the 
upregulation of ECM gene expression, it is important to determine the mechanism 
utilized by Fatp1 overexpression to induce the large transcriptional activation of ECM 
genes change.   
 
4.2.3 Repression of anti-fibrotic miR-29 in FATP1 mice 
 Recently, microRNAs has been proposed as an exciting new way of regulating 
multiple related genes or ones that fall under the same pathway (124). Various 
microRNAs modulated in the cardiovascular system have been identified and extensively 
studied (38, 125). In particular, several microRNAs have been implicated to play 
important but distinct roles to mediate cardiac fibrosis (40, 41, 43), differing in their 
cellular expressions and targeted actions. Among these microRNAs, the cardiac fibroblast 
enriched miR-29 family stood out as a potential candidate in mediating the fibrotic 
effects observed in FATP1 transgenic mice. The miR-29 family functions as an anti-
fibrotic regulator of an impressive collection of genes belonging to the ECM network by 
targeting the 3’-UTR region of its target genes mRNA for degradation(40). Since much 
of the ECM genes that were upregulated in FATP1 mice compared to control were miR-
29 targets, the expression of miR-29 levels in FATP1 and WT hearts were evaluated. The 
anti-fibrotic miR-29 was significantly downregulated in both in miR-29a by 26% and  
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Figure 51 Repression of the anti-fibrotic miR-29 family in FATP1 mice. 
Total RNA isolated from FATP1 and WT LV tissue were examined with qRT-PCR for 
the relative expressions of miR-29a, miR-29b, and miR-29c. miR-29 expressions were 
normalized to sno202 (miRNA control). n=3, *p<0.05, **p<0.01 vs. WT littermates.  
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Figure 52 c-Myc mRNA increased in FATP1 mice. 
FATP1 and WT littermate LV tissue were used to isolate RNA. The mRNA expression of 
c-Myc was analyzed with qRT-PCR and normalized to the expression level of Gapdh. 
n=6, ****p<0.0001 vs. WT littermates. 
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miR-29c by 30% as shown in Figure 51. Drawing from this data, it suggests that the 
decrease in miR-29 suppression on ECM targets enabled the increased ECM gene 
regulation seen in the Fatp1 overexpressing mice.  
 Widespread microRNA repression by c-Myc (Myc) has been extensively studied 
and reviewed (126). Strong Myc binding upstream of miR-29 start site as well as its 
repression on miR-29 expression has been reported in B-cell lymphoma mouse models 
(127, 128). In order to evaluate the activity of c-Myc expression in FATP1 mice, qRT-
PCR was utilized to determine its relative mRNA expression. The c-Myc mRNA level 
was ~4-fold higher in FATP1 mice than WT controls (Figure 52). This finding is the first 
report linking increased c-Myc with the suppression of miR-29 in cardiac fibrosis. Future 
experiments are needed to clearly delineate the c-Myc regulated miR-29 repression in 
cardiac fibroblasts in vitro as another alternative mechanism to Smad-dependent and 
Smad-independent pathways of activating fibrosis in the heart. Beyond the potential 
repressor activity of Myc on miR-29 family expression, increased Myc activity in the 
myocardium has been implicated to promote compensated cardiac hypertrophy and 
increases FFA utilization (129). Further understanding in the role of Myc in the 
pathogenesis of MHD is still needed.  
 
4.2.4 Increased cardiokines in the FATP1 heart 
Next step was to identify profibrotic cardiokines responsible for the fibrotic 
remodeling observed in FATP1 transgenic mice. Several known profibrotic factors such 
as TGF-β1, angiotensin II, and endothelin-1 have been reported to induce cardiac fibrosis  
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Figure 53 Tgf-β1 mRNA level remained unchanged in FATP1 mice. 
FATP1 and WT littermate LV tissue were used to isolate RNA. The mRNA expression of 
Tgf-β1 was analyzed with qRT-PCR and normalized to the expression level of Gapdh. 
n=6, n.s. vs. WT littermates. 
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Figure 54 Angiotensinogen expression was downregulated in FATP1 mice. 
FATP1 and WT littermate LV tissue were used to isolate RNA. The mRNA expression of 
Agt was analyzed with qRT-PCR and normalized to the expression level of Gapdh. n=6, 
***p<0.001 vs. WT littermates. 
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Figure 55 Endothelin-1 expression was downregulated in FATP1 mice. 
FATP1 and WT littermate LV tissue were used to isolate RNA. The mRNA expression of 
Edn1 was analyzed with qRT-PCR and normalized to the expression level of Gapdh. 
n=6, **p<0.01 vs. WT littermates. 
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in other models of heart failure (105-107). Not only is Tgf-β1 a predominant pathway 
utilized by many heart failure models, it has also been shown that miR-29 expression was 
down-regulated in cultured cardiac fibroblasts treated with TGF-β1(40). The expression 
of Tgf-β1 mRNA was trending down, though not statistically significant, in FATP1 mice 
compared with WT control (Figure 53). The mRNA expression of angiotensin II 
precursor angiotensinogen, Agt, was downregulated by 58% in FATP1 (Figure 54). The 
endothelial cell derived fibrotic factor endothelin-1, Edn, was also downregulated by 
52.3% in FATP1 mice compared with WT control (Figure 55). Considering Ang II can 
directly upregulate TGF-β1 (33) and ET-1 (35), its downregulation in FATP1 along with 
unchanged Tgf-β1 and decreased Edn expressions is consistent with current knowledge 
for this fibrotic signaling network. However, the lack of TGF-β1 stimulation independent 
of Ang II was surprising since TGF-β1 has been the predominant regulator of fibrosis in 
the heart in MI, PO, and aging. Since TGF-β1 does not appear to be upregulated by Fatp1 
overexpression, then it is necessary to identify the primary profibrotic cardiokine 
responsible for the observed interstitial fibrosis.  
In order to expand the scope of analysis, RNA extracted from FATP1 and WT 
littermates were submitted for a Fibrosis PCR array analysis looking at 84 gene targets 
across several fibrotic pathways. The results of the array analysis detailed in Table 5 
indicated that Tgf-β2 expression, and not Tgf-β1 or Tgf-β3, was tremendously increased 
while inflammatory markers and other pro-fibrotic chemokines were either down-
regulated or unchanged in FATP1 mice. Using qRT-PCR to validate the findings of the 
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Symbol Description 
Fold Up- or 
Down 
FATP1/WT 
Sample 
Acta2 Actin,'alpha'2,'smooth'muscle,'aorta' 1.34 
Actb Actin,'beta' -1.08 
Agt Angiotensinogen'(serpin'peptidase'inhibitor,'
clade'A,'member'8)'
-2.03 
Akt1 Thymoma'viral'proto<oncogene'1' 1.14 
B2m Beta<2'microglobulin' -1.23 
Bcl2 B<cell'leukemia/lymphoma'2' 1.65 
Bmp7 Bone'morphogenetic'protein'7' -1.09 
Cav1 Caveolin'1,'caveolae'protein' -2.12 
Ccl11 Chemokine (C-C motif) ligand 11 -4.02 
Ccl12 Chemokine'(C<C'motif)'ligand'12' 1.98 
Ccl3 Chemokine'(C<C'motif)'ligand'3' -1.08 
Ccr2 Chemokine'(C<C'motif)'receptor'2' -1.10 
Cebpb CCAAT/enhancer'binding'protein'(C/EBP),'beta' 1.25 
Col1a2 Collagen,'type'I,'alpha'2' 1.81 
Col3a1 Collagen,'type'III,'alpha'1' 1.40 
Ctgf Connective'tissue'growth'factor' 1.75 
Cxcr4 Chemokine'(C<X<C'motif)'receptor'4' -1.29 
Dcn Decorin' 1.22 
Edn1 Endothelin'1' -1.45 
Egf Epidermal'growth'factor' -5.30 
Eng Endoglin' -1.17 
Fasl Fas'ligand'(TNF'superfamily,'member'6)' -2.20 
Gapdh Glyceraldehyde<3<phosphate'dehydrogenase' 1.25 
Grem1 Gremlin'1' -13.84 
Gusb Glucuronidase,'beta' -1.47 
Hgf Hepatocyte'growth'factor' -1.37 
Hsp90ab1 Heat'shock'protein'90'alpha'(cytosolic),'class'B'
member'1'
1.57 
Ifng Interferon'gamma' -3.67 
Il10 Interleukin'10' -3.36 
Il13 Interleukin'13' -2.51 
Il13ra2 Interleukin'13'receptor,'alpha'2' -2.90 
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Il1a Interleukin'1'alpha' -1.78 
Il1b Interleukin'1'beta' -2.17 
Il4 Interleukin'4' -2.83 
Il5 Interleukin'5' -1.43 
Ilk Integrin'linked'kinase' -1.09 
Inhbe Inhibin'beta'E' -1.03 
Itga1 Integrin'alpha'1' -1.32 
Itga2 Integrin'alpha'2' -1.34 
Itga3 Integrin'alpha'3' 1.25 
Itgav Integrin'alpha'V' 1.37 
Itgb1 Integrin'beta'1'(fibronectin'receptor'beta)' 1.49 
Itgb3 Integrin'beta'3' 1.03 
Itgb5 Integrin'beta'5' 1.88 
Itgb6 Integrin'beta'6' -1.64 
Itgb8 Integrin'beta'8' 1.07 
Jun Jun'oncogene' -1.02 
Lox Lysyl'oxidase' 2.06 
Ltbp1 Latent'transforming'growth'factor'beta'binding'
protein'1' -1.83 
Mmp13 Matrix'metallopeptidase'13' -5.37 
Mmp14 Matrix'metallopeptidase'14'(membrane<
inserted)'
1.47 
Mmp1a Matrix'metallopeptidase'1a'(interstitial'
collagenase)'
-2.95 
Mmp2 Matrix'metallopeptidase'2' 1.35 
Mmp3 Matrix'metallopeptidase'3' -3.90 
Mmp8 Matrix'metallopeptidase'8' -3.93 
Mmp9 Matrix'metallopeptidase'9' -5.48 
Myc Myelocytomatosis'oncogene' 4.43 
Nfkb1 
Nuclear'factor'of'kappa'light'polypeptide'gene'
enhancer'in'B<cells'1,'p105'
-1.17 
Pdgfa Platelet'derived'growth'factor,'alpha' -1.22 
Pdgfb Platelet'derived'growth'factor,'B'polypeptide' 1.18 
Plat Plasminogen'activator,'tissue' -1.20 
Plau Plasminogen'activator,'urokinase' 1.09 
Plg Plasminogen' -34.71 
Serpina1a Serine'(or'cysteine)'peptidase'inhibitor,'clade'A,'
member'1a'
-4.23 
Serpine1 Serine'(or'cysteine)'peptidase'inhibitor,'clade'E,' 2.09 
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member'1'
Serpinh1 Serine'(or'cysteine)'peptidase'inhibitor,'clade'H,'
member'1' 1.87 
Smad2 MAD'homolog'2'(Drosophila)' 1.16 
Smad3 MAD'homolog'3'(Drosophila)' -1.04 
Smad4 MAD'homolog'4'(Drosophila)' -1.06 
Smad6 MAD'homolog'6'(Drosophila)' -1.39 
Smad7 MAD'homolog'7'(Drosophila)' -1.47 
Snai1 Snail'homolog'1'(Drosophila)' -2.06 
Sp1 Trans<acting'transcription'factor'1' -1.14 
Stat1 Signal'transducer'and'activator'of'transcription'
1'
-1.44 
Stat6 Signal'transducer'and'activator'of'transcription'
6'
1.31 
Tgfb1 Transforming'growth'factor,'beta'1' -1.41 
Tgfb2 Transforming+growth+factor,+beta+2+ 6.83 
Tgfb3 Transforming'growth'factor,'beta'3' 1.17 
Tgfbr1 Transforming'growth'factor,'beta'receptor'I' -1.02 
Tgfbr2 Transforming'growth'factor,'beta'receptor'II' 1.31 
Tgif1 TGFB<induced'factor'homeobox'1' 1.14 
Thbs1 Thrombospondin'1' 1.43 
Thbs2 Thrombospondin'2' 1.06 
Timp1 Tissue'inhibitor'of'metalloproteinase'1' 2.85 
Timp2 Tissue'inhibitor'of'metalloproteinase'2' -1.18 
Timp3 Tissue'inhibitor'of'metalloproteinase'3' -1.64 
Timp4 Tissue'inhibitor'of'metalloproteinase'4' -2.44 
Tnf Tumor'necrosis'factor' -1.91 
Vegfa Vascular'endothelial'growth'factor'A' -2.01 
 
 
Table 5 PCR Array results. 
RNA isolated from FATP1 and WT ventricular tissues were submitted to the BU 
analytical core to run the Fibrosis RT2 PCR Array. N=2 for each genotype were used. No 
statistical analysis was performed. 
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PCR array, a 3.6-fold increase in Tgf-β2 mRNA level was indeed found in the FATP1 
transgenic mice compared with WT littermates (Figure 56). Similarly, the mature TGF-
β2 protein expression increased by 56.7% in FATP1 heart lysates compared to WT 
control samples (Figure 57). This finding was consistent with HFHS diet fed mouse data. 
Thus, the expression of the cardiokines FSTL3 identified earlier in Chapter 3 was also 
examined in FATP1 mice. Using qRT-PCR and immunoblotting techniques, the Fstl3 
mRNA level was increased by 2-fold and protein level was also increased by ~2-fold, as 
shown in Figure 58 and 59, respectively. Although Fst3 did not appear to have 
profibrotic effects in the in vitro experiments described in Chapter 3, the fact that it is 
also induced in yet another mouse model of MHD implicates that it has a functional role 
in the disease pathology. 
This is the first observation in a model of HF where only TGF-β2 is elevated in 
the myocardium. Though the heart expresses all three isoforms of TGF-β, it has been 
predominantly TGF-β1 that is elevated to induce cardiac fibrosis. Of the knockouts mice 
specific for each isoform, only TGF-β2 null mice develop severe cardiac developmental 
defects before they succumb to perinatal mortality (71, 72). Only a handful of reports 
have indicated an upregulation of TGF-β2 in the myocardium in association with cardiac 
fibrosis. Deten et. al. observed in the rat coronary artery ligation model that both TGF-β1 
and TGF-β2 are elevated early, a couple days post-MI (66). There has been no other 
report in mouse HF models where TGF-β2 is elevated in concert with TGF-β1. Without a 
viable knockout mouse model of TGF-β2, it has been difficult to elucidate its role in vivo  
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Figure 56 Tgf-β2 mRNA was increased in FATP1 
FATP1 and WT littermate LV tissue were used to isolate RNA. The mRNA expression of 
Tgf-β2 was analyzed with qRT-PCR and normalized to the expression level of Gapdh. 
n=6, ****p<0.0001 vs. WT littermates. 
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Figure 57 TGF-β2 protein was increased in FATP1 
Tissue lysates made from FATP1 and WT LV were used to immunoblot for TGF-β2 
protein expression. All values represent mean ± standard error, n=4, **p<0.01 vs. WT 
littermate animals. 
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Figure 58 Fstl3 mRNA was increased in FATP1. 
Cardiac myocytes were isolated from FATP1 and WT mice. RNA isolated from the 
myocytes were probed for the expression of Fstl3 using qRT-PCR and normalized to the 
expression of Gapdh. All values represent mean ± standard error, n=3, **p<0.01 vs. WT 
littermate animals. 
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Figure 59 FSTL3 protein was increased in FATP1 
Tissue lysates made from FATP1 and WT LV were used to immunoblot for TGF-β2 
protein expression. All values represent mean ± standard error, n=4, ****p<0.0001 vs. 
WT littermate animals. 
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in the post-natal heart. Therefore, this observation of increased TGF-β2 is an exciting and 
novel finding. Given that TGF-β2 is increased with both the metabolic diet feeding and 
Fatp1 overexpression, suggests a lipid regulation of TGF-β2 in the heart.  Albeit it is still 
plausible that TGF-β isoforms have temporal control of their transcription leading us to 
only see elevated levels of TGF-β2 at 2 months of age. 
4.2.5 Tgf-β2 and Fstl3 are up-regulated in the FATP1 myocytes 
 Having identified Tgf-β2 and Fstl3 as cardiokines up-regulated in FATP1 mice, 
the next step was to evaluate whether cardiomyocyte was the source of the increased 
expression. RNA extracted from freshly isolated cardiomyocytes from FATP1 and WT 
mouse hearts were probed for the relative expression of the cardiokines of interest. 
Shown in Figure 60, myocyte Tgf-β2 mRNA expression was increased by 3.8-fold in the 
FATP1 mice compared to WT. Similarly, Fstl3 mRNA expression increased by 1.9-fold 
in FATP1 mice compared to WT (Figure 61). The observation that both Tgf-β2 and Fstl3 
were induced in the cardiac myocytes of FATP1 mice differs slightly from the HFHS diet 
fed mice where Tgf-β2 was increased only in the non-myocyte fraction. This discrepancy 
could be attributed to the fact that in the FATP1 transgenic animals only cardiomyocytes 
experienced the stress of increased FFA overload whereas other cells such as fibroblasts, 
endothelial cells, and vascular smooth muscle cells only respond to factors secreted by 
the cardiomyocytes rather than the primary insult. The converse is true of a diet-feeding 
model where all cell types and organs respond to the altered composition of their diet. 
Tgf-b proteins are known to function in an autocrine and paracrine manner (cite) that can  
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Figure 60 Myocyte Tgf-β2 expression was significantly induced in FATP1 mice. 
Cardiac myocytes were isolated from FATP1 and WT mice. RNA isolated from the 
myocytes were probed for the expression of Tgf-β2 using qRT-PCR and normalized to 
the expression of Gapdh. All values represent mean ± standard error, n=4, *p<0.5 vs. WT 
littermate animal. 
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Figure 61 Myocyte Fstl3 expression was significantly induced in FATP1 mice. 
Cardiac myocytes were isolated from FATP1 and WT mice. RNA isolated from the 
myocytes were probed for the expression of Fstl3 using qRT-PCR and normalized to the 
expression of Gapdh. All values represent mean ± standard error, n=4, *p<0.01 vs. WT 
littermate animal. 
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produce and receive the extracellular signaling binding to its receptors. With the lack of 
non-myocyte data collected from FATP1 transgenic mice, it cannot be completely ruled 
out that the non-myocytes could also up-regulate Tgf-β2 expression in response to the 
increased secretion of Tgf-β2 from myocytes in paracrine fashion rather than just 
responding to the extracellular Tgf-β2 signal with intracellular signal activation. 
4.2.6 PMA treated ARVMs induce TGF-β2 
 It has been previously reported by the lab that PKCα and PKCδ phosphorylation 
levels were elevated in FATP1 mice compared to control littermates (95).Thus, it was 
postulated that PKC activation is upstream of TGF-β2 synthesis in cardiomyocytes. To 
test this hypothesis, cultured ARVMs were treated with a pan-PKC activator, phorbol 12-
myristate 13-acetate (PMA), and the expression of TGF-β2 was measured with 
immunoblotting. ARVMs treated with 100 µM PMA for 24 hours induced ~30% increase 
in TGF-β2 protein expression (Figure 62). The slight increase in TGF-β2 in the PMA 
treated ARVMs could indicate the one of a few things: 1) PKC activity only partially 
contributes to the increased synthesis of TGF-β2, 2) too many PKC isoforms activated by 
PMA that their combined activity on TGF-β2 synthesis muted the PKCα and δ effect, or 
3) the dosage of PMA has yet to be optimized to see the maximal synthesis of TGF-β2.  
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Figure 62 PMA-treated ARVMs induces TGF-β2. 
ARVMs were treated with either PMA (100 nM) or DMSO (vehicle control) in culturing 
ACCT media for 24 hours. Cell lysates were immunoblotted for TGF-β2 protein 
expression. Immunoblots were quantified by densitometry (Odessey). All values 
represent mean ± standard error, n=3, *p<0.05 vs. control condition. 
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4.3 Conclusion 
  The goal of this study was to elucidate the profibrotic cardiokine induced by the 
cardiac-specific overload of FFA model of MHD. The FFA overload achieved with 
Fatp1 overexpression in cardiomyocytes, which led to significant cardiac interstitial 
fibrosis and diastolic dysfunction. This study identified a novel TGF-β2 upregulation in 
the myocytes, rather than TGF-β1, as the primary profibrotic cardiokine induced by 
FATP1 overexpression. Suppression of the anti-fibrotic miR-29 family resulted in the 
overall upregulation of its ECM target genes in FATP1 mice. Increased level of c-Myc 
was postulated to suppress miR-29 in the Fatp1 overexpressing mice. Also found 
upregulated was the FSTL3 cardiokine, the exact function of which in MHD remains to 
be determined.  
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 With the rise in obesity and metabolic syndrome, the combined risk for 
developing metabolic heart disease (MHD) and eventually heart failure represents a 
substantial burden both on human life and economy. The pathophysiological hallmarks of 
MHD include increased left ventricular hypertrophy, diastolic dysfunction with preserved 
ejection faction, and fibrosis. Fibrosis is the adverse remodeling resulting from excess 
accumulation of extracellular matrix components, primarily the collagen fibers. The 
development of fibrosis has been linked to the increased deterioration in both systolic and 
diastolic functions (16, 30, 130). Autocrine, paracrine, and endocrine proteins secreted 
from the heart, collectively referred to as cardiokines, have been described when the 
heart is under the stress of myocardial infarction (102, 131, 132) or pressure overload 
(81, 101, 133, 134), but MHD induced cardiokines have yet to be fully examined. The 
pleiotropic TGF-β family proteins have regulatory roles in diverse biological and 
pathological processes, including fibrosis. The TGF-β1 is the most notable isoform due to 
its global expression in most organs and cell types, whereas TGF-β2 and TGF-β3 have 
more limited expression and their roles in vivo have not been well characterized. 
 In this project, two phenotypically relevant mouse models were used to 
thoroughly study the synthesis of profibrotic cardiokines in the context of MHD. First, 
the HFHS diet feeding model mimics human diet-induced obesity. Mice fed HFHS for 
four months developed diastolic dysfunction, preserved systolic function, and significant 
ventricular interstitial fibrosis. It was found that both Tgf-β1 and Tgf-β2 isoforms were 
upregulated in the non-myocytes, most likely activated fibroblasts, in response to the 
HFHS diet feeding. The profibrotic activity of TGF-β2 was confirmed with the increased  
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Figure 63 Summary of cardiokines induced by dietary excess model of MHD. 
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phosphorylation of SMAD signaling and increased collagen III production in cultured 
mouse embryonic fibroblasts and adult rat cardiac fibroblasts treated with recombinant 
TGF-β2. The findings of this model is summarized in Figure 63. 
 The second mouse model was a transgenic animal overexpressing the Fatp1 
transgene specifically within the cardiomyocytes to mimic the increased myocardial FFA 
uptake commonly found in patients with metabolic syndrome. In the Fatp1 
overexpressing mice, TGF-β2 was upregulated whole heart and specifically in the 
cardiomyocytes. Whereas mRNA levels of Tgf-β1 was not changed by the transgene 
overexpression, angiotensinogen and endothelin-1 were downregulated in FATP1 mice. 
Alongside TGF-β2 upregulation was the activation of ECM gene regulation of collagen I, 
III, and IV, elastin, fibronectin, and fibrillin, which are all gene targets of miR-29 that 
was downregulated in FATP1 mice in comparison to WT. The transcriptional repressor 
role of c-Myc on miR-29 expression has been reported in B-cell lymphoma (127) and the 
observation of elevated c-Myc levels in FATP1 mice suggests a similar role in mediating 
cardiac fibrosis through the suppression of miR-29. The findings on cardiokines induced 
by FATP1 overexpression and the activate fibrotic signaling pathways are represented in 
Figure 64.  
 Follistatin-like 3 (FSTL3) was also identified as a cardiokine upregulated in the 
myocytes of both HFHS-fed and FATP1 mice, compared to their respective control 
animals. FSTL3 did not appear to have a direct fibrotic effect as concluded from its 
inability to neither phosphorylate fibrotic signaling of SMAD and non-SMAD proteins 
nor increased collagen protein synthesis in fibroblast cultured treated with recombinant  
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Figure 64 Summary of cardiokines induced by FATP1 overexpression-driven 
cardiac lipid accumulation. 
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FSTL3. Despite this negative finding, FSTL3 was significantly elevated in the plasma of 
metabolic syndrome patients increasing with the severity in the parameters for LV mass 
and diastolic function. FSTL3 levels also correlated positively with LV mass and 
negatively with tissue doppler velocity (Em). This observation suggests the relevance of 
the secreted FSTL3 in metabolic syndrome and confirms its role in cardiac hypertrophy 
(81). Therefore, cardiac-specific FSTL3 knockouts (KO) were generated and will be put 
on the HFHS diet to test if the ablation the Fstl3 in cardiomyocytes can rescue the 
hypertrophic phenotype caused by the metabolic diet. Preliminary heart weight data 
collected from KO and control mice fed HFHS diet for 1 month suggests a trend towards 
decreased heart weight in KO mice compared to control, albeit not statistically 
significant. Definitive effects of cardiac Fstl3 ablation on LV hypertrophy will need to be 
determined at 4 months on diet feeding. Together with the metabolic syndrome human 
data, an opportunity exists for FSTL3 to become a novel biomarker to of cardiac 
hypertrophy in metabolic syndrome patients where BNP the classic plasma marker of 
hypertrophy(53, 54), is not induced.  
 Taken together, these findings clearly delineate an induction of profibrotic 
cardiokines in the event of a metabolic imbalance (Figure 65). Both the diet study and 
the transgenic animal are tools engineered to uncover different aspects of the underlying 
mechanisms of MHD induced fibrosis. It is equally informative to have found that with 
the HFHS diet feeding non-myocytes, most likely activated fibroblasts, increased 
synthesis of profibrotic TGF-β1 and TGF-β2 that activated the fibrotic pathway as it is 
was to have found that lipid overload specifically restricted to the cardiomyocytes was  
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Figure 65 Conclusion on the role of cardiokines induced in MHD. 
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sufficient to induce fibrosis through the upregulation of TGF-β2 in the cardiomyocytes. 
Current information about the in vivo function of TGF-β2 in the heart has been limited 
due to the perinatal lethality caused by the deletion of the Tgf-β2 gene (135). Thus, the 
elevated levels of TGF-β2 without concurrent TGF-β1 upregulation found in FATP1 
mice in comparison to WT animals implicates its sufficiency to induce cardiac fibrosis 
and suggests lipid induced isoform specificity. Additionally, the observation that miR-29, 
a repressor of ECM components, was downregulated in the FATP1 transgenic mice 
compared to WT animals reveals another layer of fibrotic regulation in the heart that has 
only recently been describe in response to MI (40), and now to MHD. This finding was 
particularly interesting as it invites the possibility of developing miRNA specific 
therapies to target the overactive ECM production in the case of pathological fibrosis. As 
opposed to the TGF-β1 neutralizing therapies that result in severe side effects as TGF-β1 
has diverse regulatory roles besides stimulating fibrosis, a miRNA therapy could have 
advantages for targeting a group of related ECM genes and can be engineered to the 
specified organ that is affected. 
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